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Abstract 
Fe65 is an adaptor protein able to interact with many different partners. Several 
results supposed the possible involvement of Fe65 in the cell response to DNA 
damage (DDR). Indeed, Fe65 null mice are more sensitive to genotoxic stress 
and this increased sensitivity appears to be dependent, at least in part, on 
defects of DNA repair. Many results indicate that the suppression of DDR 
plays an important role in tumor development and progression. Mutations of 
various members of the DDR pathway often result in an increased 
tumorigenesis. To investigate the involvement of Fe65 in tumor development I 
analyzed the phenotype of primary embryonic fibroblasts (MEFs) derived from 
Fe65-/- mice. I found that the apoptosis induced by ionizing radiations, UV 
rays or Myc ectopic expression is lower in Fe65-/- primary MEFs. This effect 
is accompanied by an increase in proliferation rate with an altered cell cycle 
kinetics. Despite a normal phosphorylation of p53, Fe65-/- MEFs failed to 
accumulate BAX and PUMA mRNAs upon DNA damage. Furthermore, Fe65  
-/- MEFs showed an increase of the basal levels of the phosphorylated form of 
AKT, which was accompanied by a slight decrease of the amount of PTEN. It 
was previously demonstrated that Fe65 interacts with JNK1 and γ-H2A.X. 
Fe65 suppression prevents the co-immunoprecipitation of these two proteins, 
thus suggesting that the resistance to apoptosis in Fe65-/- MEFs could be, at 
least in part, a consequence of the reduced activation of JNK-dependent pro-
apoptotic pathway. While, as expected, early passage wild type primary MEFs 
are poorly sensitive to Myc-induced transformation, Myc overexpression 
induced the growth of a significant number of colonies of Fe65-/- cells. 
Similarly, the silencing of Fe65 in NIH3T3 cells significantly enhanced the 
transforming efficiency of oncogenic Ras. Furthermore, I found that Fe65 
expression is reduced both in a transformed cell line and in human tumors and 
this effect doesn’t depend on gene deletion or promoter methylation. These 
results suggest the possibility that Fe65 is a tumor suppressor gene. 
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Background 
1 Alzheimer’s disease  
 Alzheimer’s disease (AD) is a slowly progressive neurodegenerative 
disorder that represents the most common form of dementia. This disorder is 
characterized by two pathological features that are observed post mortem: 
amyloid plaques and neurofibrillary tangles in the cerebral cortex and limbic 
system, which are unanimously recognized as the hallmarks of the disease. 
Alzheimer’s disease is a heterogeneous syndrome with both familial and 
sporadic forms. Familial AD is an autosomal dominant disorder with onset 
before 65 years. Four genes have been unequivocally implicated in inherited 
forms of AD and mutations or polymorphisms in these genes cause excessive 
cerebral accumulation of amyloid ß-peptides and subsequent neuronal and glial 
pathology in brain regions important for memory and cognition. The first 
mutation causing the familial form of the disease was identified in the amyloid 
precursor protein (APP) gene on chromosome 21 (St George-Hyslop et al., 
1990), however mutations of this gene explain only a few familial cases. 
Indeed in 1995 mutations in the highly homologous presenilin 1 (PSEN1) and 
presenilin 2 (PSEN2) genes were also linked to early-onset familial AD (Levy-
Lahad et al., 1995) (Rogaev et al., 1995) and they account for most cases of 
familial disease.  
 At microscopic level, the characteristic lesions in Alzheimer’s disease 
are senile or neuritic plaques and neurofibrillary tangles (Figure 1) in the 
medial temporal lobe structures and cortical areas of the brain, together with a 
degeneration of the neurons and synapses. The plaques are composed primarily 
of the 39–43-residue amyloid β-peptide (Aβ) (Wolfe, 2006). Aβ is released 
from the amyloid precursor protein (APP) by the sequential action of β- and γ-
secretases, with the latter cutting relatively heterogeneously (Esler and Wolfe, 
2001). Most of the Aβ produced by γ-secretase is the 40-residue form (Aβ40); 
however, the major Aβ species deposited in the plaques is the 42-residue 
variant (Aβ42), although this peptide represents only 5–10% of all Aβ 
produced.  
 Neurofibrillary tangles are large, non membrane bound bundles of 
abnormal fibers that accumulate in the perinuclear region of cytoplasm. 
Electron microscopy reveals that most of these fibers consist of pairs of 10-nm 
filaments wound into helices (paired helical filaments or PHF), composed of 
the microtubule-associated protein Tau (Wood et al., 1986) which is present in 
a hyperphosphorylated form. A variety of kinases have been shown to be able 
of phosphorylating Tau in vitro at various sites (Martin et al., 2011) that leads 
to its apparent dissociation from microtubules and aggregation into insoluble 
paired helical filaments.  
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Figure 1: Plaques and tangles in the cerebral cortex in Alzheimer’s disease  
Plaques are extracellular deposits of Aβ surrounded by dystrophic neurites, 
reactive astrocytes, and microglia, whereas tangles are intracellular aggregates 
composed of a hyperphosphorylated form of the microtubule-associated protein Tau. 
  
 
Genetic and pathological evidence strongly supports the amyloid 
cascade hypothesis of AD, which states that Aβ42 has an early and vital role in 
all cases of AD. Indeed APP mutations associated with early-onset dominant 
AD are located in and around the Aβ region of APP or of the presenilin genes, 
which encode the catalytic activity of γ-secretase (Bertram et al., 2010). These 
mutations were soon determined to alter the amount of Aβ produced, the ratio 
of Aβ42 to Aβ40 or the amino-acid sequence of Aβ (Selkoe and Kopan, 2003). 
  Experimental evidence supports the possibility that APP and/or γ-
secretase dysfunction could lead to neurodegeneration (Robakis, 2011). 
Obviously, the understanding of the functions of APP and of its processing is 
crucial to explore loss of function hypotheses in the pathogenesis of AD. 
In 1995, we observed that the NPXY motif present in the small 
cytodomain of APP interacts with a PTB/PI domain of a protein of unknown 
function, named Fe65 (Fiore et al., 1995) (Simeone et al., 1994). 
 
2 The Adaptor Protein Fe65 
 Fe65, together Fe65L1 and Fe65L2 (its paralogs in mammals), is a 
member of a multigene family of adaptor proteins which share three highly 
conserved protein-protein interaction domains (Minopoli et al., 2012). 
Although ubiquitous, Fe65 is expressed at high levels in neurons (Bressler et 
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al., 1996), and its expression is developmentally regulated, with levels 
declining after embryonic day 15 and increasing again progressively from 
postnatal day 10 to adulthood (Simeone et al., 1994) (Kesavapany et al., 2002). 
 The Apbb1 gene encoding Fe65 was identified by a screen as a mRNA 
expressed at high levels in the brain (Esposito et al., 1990), and subsequently it 
was found evolutionary conserved from nematode to human (Zambrano et al., 
2002). Fe65 mRNA encodes a protein of 711 amino acids with molecular 
adapter features; indeed it has three different protein–protein interaction 
domains, a WW domain and two consecutive PTB domains (Zambrano et al., 
1997a) (Figure 2).  
 
 
 
 
 
Figure 2: Schematic representation of Fe65 protein. 
 The regions corresponding to the three protein-protein interaction domains, 
the WW domain (green) with its interactors (Mena - Abl - Set) and the two domains 
PTB1 and PTB2 (blue and grey) and their cognate ligands (LSF - Tip60 - LRP for 
PTB1 and APP - APLP1 - APLP2 for PTB2). 
 
Through screenings for Fe65 binding partners, many proteins that 
interact with Fe65 were identified. One of these is APP and its related protein 
APLP1 and APLP2 that interact with Fe65 PTB2 domain. In particular Fe65 
bind the NPTY-containing region of all APP and APP-like proteins. 
Furthermore, it was identified the small G-protein Dexras1 as a novel 
interacting partner of Fe65 PTB2 domain. This interaction is regulated by the 
phosphorylation of Fe65 on Y547. Dexras1 inhibited FE65-mediated 
transcription without an apparent effect on binding of FE65 to APP, so 
defective FE65 phosphorylation could lead to transcription of potential FE65-
APP-regulated genes such as BACE, GSK3β, and APP, which are linked to the 
pathogenesis of Alzheimer disease (Lau et al., 2008). PTB1 domain of Fe65 
binds the transcription factor CP2/LSF/LBP1 (Zambrano et al., 1998) and this 
interaction is implicated in the regulation of transcription of GS3Kβ (glycogen 
synthase kinase−3β) (Kim et al., 2003) and timidilate synthase (Bruni et al., 
2002). Another strong interactor of Fe65 PTB1 is the histone acetyltransferase 
Tip60 (Cao and Sudhof, 2001). In addition to CP2/LSF and Tip60 the PTB1 
has also been found to interact with LRP (Waldron et al., 2006), which is a 
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receptor for ApoE and α-2 macroglobulin, also involved in the scavenging 
secreted Aβ (Trommsdorff et al., 1998). Fe65 also binds, through its PTB1 
domain, another member of the LRP family, the ApoER2 (Hoe et al., 2006). 
The complex between Fe65 and the members of the LDL-related proteins 
might affect the APP processing. Furthermore, Fe65 PTB1 domain interacts 
with the other protein involved in Alzheimer’s disease, Tau protein, and their 
interaction is regulated by Tau phosphorilation (Barbato et al., 2005). The WW 
domain is the most N-terminal domain of the three protein interacting domains. 
It has been demonstrated to interact with Mena, a member of ENA/WASP 
family, which is involved in actin remodelling (Ermekova et al., 1997); c-Abl, 
a tyrosine kinase, which phosphorylates APP on Y682 (Zambrano et al., 2001) 
and Fe65 on Y547  (Perkinton et al., 2004) and finally, SET, a member of 
INHAT complex, and Teashirt3 (Kajiwara et al., 2009) involved in the 
chromatin remodeling (Telese et al., 2005).  
 
2.1 Fe65 functions 
 The function of Fe65 is still not understood. Relevant information about 
the possible functions of Fe65 comes from the analysis of knock-out animals. 
In Caenorhabditis elegans there is a single gene coding for a protein very 
similar to mammalian Fe65. This ortholog, called feh-1, has the same 
multimodular structure of mammalian Fe65s; indeed, it interacts with the 
nematode ortholog of APP, aph (Zambrano et al., 2002). The feh-1-null worms 
are not compatible with proper development of C. elegans: due to a block at 
the embryonic stage. Embryonic arrest phenotype results in severe 
developmental defects, leading to disorganized embryos, with cells that either 
detach or degenerate. Heterozygous worms, instead, presented an elevated 
rhythm of pharyngeal contractions and hyperactive head movements. (Bimonte 
et al., 2004). The phenotype of feh-1-null worms is very similar to that caused 
by the suppression of the nematode ortholog of APP. The ablation of Fe65 by 
gene targeting in mice didn’t show any macroscopic phenotypes, likely due to 
gene redundancy. Indeed, the double knock-out of Fe65 and Fe65L1 genes 
shows significant defects in the development of the central nervous 
system(Guenette et al., 2006) that resemble those observed in the 
APP;APLP1;APLP2 gene knock-out mice (Herms et al., 2004). This 
observation suggests that Fe65 and APP are involved in common mechanisms. 
Mice lacking Fe65 look like normal but they may have some not evident 
phenotypes. First of all, the absence of Fe65 enhances neurogenesis (Ma et al., 
2008), like APP knock-out mice, and suppresses the GnRH-1 neurogenic 
program (Forni et al., 2011); then, it is involved also in impairment in the 
memory and learning (Wang et al., 2004). Recently, it was demonstrated that 
Fe65 null mice are more sensitive to DNA-damaging agents (Minopoli et al., 
2007). More information about possible functions of Fe65 came from study on 
cellular system. Among the identified biding partners of Fe65 there are both 
 6 
 
cytosolic and nuclear proteins thus suggesting that Fe65 could have function in 
both cellular compartments. 
2.2 Cytosolic Fe65 
All three Fe65 proteins form complexes in vivo with APP, APLP1 and APLP2, 
suggesting that Fe65 could be involved in the proteolytic processing of these 
proteins. 
APP is a type I membrane protein with a large glycosylated 
extracellular/intraluminal (EC/IL) domain, a single transmembrane tract, and a 
short cytosolic domain (Figure 3). APP undergoes a complex proteolytic 
processing by three different enzymatic activities called α, β and γ –secretases. 
The first event involves the release of the large extracellular domain. This can 
be generated by two different enzymes, the α - or β –secretase. The α-secretase 
interrupts the sequence of the peptide Aβ, preventing its production, and 
releases the soluble fragment sAPPα. Alternatively, the cut can be catalyzed by 
the aspartil protease BACE (β -APP cleaving enzyme), which releases large 
soluble fragment sAPPβ and cleaves APP at the N -terminus of the Aß peptide, 
initiating the amyloidogenic pathway. The fragments C83 and C99, anchored 
to the membrane after the cleavage of APP by α - or β -secretase, become 
substrates of γ -secretase, which catalyzes the intramembrane cutting. This 
event releases the non- neurotoxic fragment P3, after the α -secretase action, 
and the Aβ peptide, when APP is cleaved by β –secretase.  Aβ peptide is very 
hydrophobic and its aggregation causes the formation of soluble oligomers. 
The accumulation of such oligomers gives rise to large insoluble aggregates 
that form the senile plaques. In both proteolytic pathways, the action of γ-
secretase releases the cytosolic domain AICD (APP Intra Cellular Domain).  
 
 
                  
Figure 3: APP and its interactors. 
 The cytosolic tail of APP is reported with the GYENPTY motif in red. Some 
of the PTB-containing proteins that interact with AICD are shown. It is represented 
the Tyr residue phosphorylated by Abl and involved in the binding to activated Abl 
and Src tyrosine kinases.  
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The dominant signal for APP endocytosis resides in the motif YENPTY but 
also other signals in the C-terminus of APP could be involved in the APP 
trafficking, which determines APP processing and so, Aβ production (Perez et 
al., 1999). The YENPTY motif is the binding site of Fe65, this suggested that 
the binding of Fe65 to APP could influence the endocytosis and in turn the 
processing. Data addressing this point showed discordant results; indeed, there 
are reports indicating that Aβ production is increased by Fe65 overexpression 
(Sabo et al., 1999) and reduced by Fe65 knockdown (Xie et al., 2007); on the 
other hand, other studies reported that Fe65 overexpression increased sAPPα 
and decreased Aβ production (Ando et al., 2001). This problem is difficult to 
understand for the complexity protein–protein interaction network centered at 
the YENPTY motif of the cytodomain of APP and for the variable abundance 
of secretases in the different cellular type. 
 Fe65 is involved, in the cytosol, also in cytoskeleton remodeling and in 
cell movement. Indeed, it interacts with Mena by the WW domain. Mena is a 
cytoskeleton regulatory protein involved in the regulation of cell motility and 
adhesion(Kwiatkowski et al., 2003). Mena binds actin and thus links Fe65 and 
APP to motility and cell morphology and to cytoskeletal dynamics (Sabo et al., 
2001). Indeed, it was well demonstrated that the Fe65/Fe65L1  DKO mice 
(Guenette et al., 2006) and those of the triple KO of APP/APLP1/APLP2 
(Herms et al., 2004) or Mena/VASP/EVL (Santiard-Baron et al., 2005) have the 
same phenotypic abnormalities, suggesting a functional interaction between 
these three protein families during neuronal development in vivo. Furthermore, 
it is known that Dab1, the mammalian ortholog of Drosophila disabled, binds 
APP and together Abl (Fe65 ligand) antagonizes the effects of Mena on 
cytoskeleton remodeling and cell movement. All these proteins compete to 
regulate the motility and the morphology of the cytoskeleton. Indeed, Mena 
and c-Abl compete for the interaction to Fe65 WW domain whilst Dab1 and c-
Abl compete for the biding to APP. It has been suggested that the Fe65 
interactions could be regulated by conformational changes (Cao and Sudhof, 
2001).  A possible model that could explain the regulation of the Mena activity 
is focused on the mutually exclusive interaction of Dab1 and Fe65 to APP 
cytodomain. Whether Dab1 binds to APP, Mena can’t interact with Fe65 
because it is in a ‘‘closed’’ conformation due to the intramolecular interaction 
of the WW domain with the PTB2 domain. In these conditions Mena is unable 
to interact with Fe65 and it is available to regulate the cytoskeleton. The Fe65 
PTB2 biding to APP led the transition of Fe65 to the “open” conformation that 
unmasks the WW domain. In this way Mena is in its inactive form. When c-
Abl was activated it can compete with Mena for the interaction with Fe65; 
allowing Mena to switch from inactive to active form. Clearly, in this context, 
there are other partners of Fe65 or APP that can play a role in remodeling of 
cytoskeleton. 
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2.3 Nuclear Fe65 
 Previous results suggested that Fe65 could have some nuclear 
functions, considering its presence in the nucleus and its interaction with 
several nuclear proteins. These results supported the hypothesis that Fe65 
could be involved in nuclear functions and that APP could regulate these 
functions. Indeed, Fe65 overexpression results in its accumulation in the 
nucleus and APP functions as an extranuclear anchor that prevents Fe65 
nuclear translocation (Minopoli et al., 2001). It was observed that the 
cotrasfection of Fe65 and APP in cultured cells causes the complete exclusion 
of Fe65 from the nucleus. A mutant GFP-Fe65 protein lacking of PTB2 
domain or with a point mutation in this domain, that affects the binding with 
APP, is always translocated into the nucleus even if the cell co-expresses APP. 
Furthermore, the C-terminal fragment of APP resulting from the cleavage 
catalyzed by γ-secretase was found in the nucleus associated with Fe65 
(Kimberly et al., 2001). The localization in the nucleus of Fe65 by APP could 
be regulated by the cleavage of γ-secretase that releases the Fe65/AICD 
complex. So, Fe65 is not anchored to the membrane, then it translocate to the 
nucleus. On the other hand, Fe65 can translocate into the nucleus by 
competition with other ligand of the APP cytosolic domain. The last is a small 
structure and Fe65, X11 and mDab1 compete among themselves to this 
domain. This competition and the resulting displacement can be determined by 
the increase in concentration of one of the two competitors, or by an increase in 
APP affinity for one or for both. The increase in affinity may be due to a 
conformational change of X11 and / or mDab1, for example mediated by post-
translational modification. 
 Finally, the phosphorylation of threonine 668 of APP cytodomain 
decreases the affinity of APP for Fe65. Therefore, another possible mechanism 
is that this phosphorylation induces a conformational change in APP 
cytodomain, which causes the release of Fe65 and its translocation into the 
nucleus (Ando et al., 2001). 
 Fe65 could have some roles in transcription activation; indeed, it 
interacts with CP2/LSF/LBP1 and Tip60. In this function, the nuclear 
localization of Fe65 could be dependent from the cytosolic fragment of APP, 
AICD. The potential importance of AICD in this mechanism was suggested by 
the recognition of similarities between APP and another type I transmembrane 
protein, Notch. Notch is a single transmembrane receptor consisting of the 
extracellular region, a heterodimerization domain and the membrane-tethered 
intracellular domains (Kimberly et al., 2001). Also Notch is cleaved by γ-
secretase that, during its proteolytic processing, allows to release the Notch 
cytosolic domain (NCID). This domain binds to the CSL protein and goes to 
the nucleus, where activates the transcription of downstream genes. Similary, 
after the proteolytic cleavage of APP, the AICD-Fe65-Tip60 complex goes to 
the nucleus where it could regulate gene transcription. Several genes have been 
suggested to be direct targets of AICD–Fe65, like APP itself, BACE, Tip60, 
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KAI1, LRP, neprilysin, and Stathmin1(von Rotz et al., 2004) (Baek et al., 2002) 
(Pardossi-Piquard et al., 2005) (Muller et al., 2012). However, AICD 
overexpression or γ-secretase inhibition doesn’t cause significant effects on  
protein levels of genes that were suggested to be regulated by AICD (Hass and 
Yankner, 2005) (Hebert et al., 2006). Therefore, the mechanism of the AICD-
dependent gene regulation is still understood.  
 
3 DNA damage response (DDR) 
 The integrity of genetic information is essential for species survival. All 
organisms are exposed to DNA damaging agents as part of everyday life. To 
counteract damages to DNA, the cells have evolved mechanisms – collectively 
termed the DNA-damage response (DDR) – to detect DNA lesions, signal their 
presence and promote their repair (Ciccia and Elledge, 2010). Cells defective 
in these mechanisms generally display increased sensitivity towards DNA-
damaging agents and many such defects cause human diseases. The DDR is a 
hierarchical process which is involved in an intricate signal transduction 
pathway that has the ability to sense DNA damage and transduce this 
information to the cell to influence cellular responses to DNA damage. Indeed, 
this process can be divided into three steps. First, localization of DDR factors 
to sites of DNA damage is initiated by DDR-sensor proteins (DDRS) that 
directly recognize specific DNA lesions and activate the DDR. Following the 
recognition of the damage, other proteins, called DDR-transducer protein 
(DDRT), are recruited on the site of the lesion to transmit the signal to the last 
series of proteins involved, called DDR-effector protein (DDRE). The lasts 
conduct different functions, including: to repair materially damage, to regulate 
the cell cycle during the repair, to modify gene transcription and, in the case of 
irreparable damage, to trigger a death program. This response culminates in the 
activation of cellular checkpoints and activation of the appropriate repair 
system, or alternatively, in the initiation of a program of death (Jackson and 
Bartek, 2009).  
 The DDR is primarily mediated by proteins of the phosphatidylinositol 
3- kinase-like protein kinases (PIKKs) family — ATM, ATR and DNA-PK — 
and by members of the poly (ADP) ribose polymerase (PARP) family (Ciccia 
and Elledge, 2010).  The DDR regulates physiological processes such as the 
decision to activate apoptosis program, differentiation, senescence, activation 
of enhanced immune surveillance, DNA repair (Cui et al., 2007) (Gasser and 
Raulet, 2006) (Zhou and Elledge, 2000). The assembly of the DDR cascade is 
dependent on a broad spectrum of post-translational modifications such as: 
phosphorylation, ubiquitination, sumoylation, poly ADPribosylation, 
acetylation, methylation that are induced by the activation of the DNA damage 
response (Bergink and Jentsch, 2009) (Harper and Elledge, 2007). These post-
translational modifications regulate the recruitment of the DDR proteins to 
DNA damage sites. Phosphorylation acts as a molecular switch for many 
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regulatory events in signalling pathways that drive cell division, proliferation, 
differentiation, and apoptosis. Kinases and phosphatases proteins have a spatial 
distribution in the cells, to ensure an appropriate balance of protein 
phosphorylation. This spatial separation regulates protein phosphorylation that, 
in turn, regulates the activity of other proteins, enzymes, and the transfer of 
other post-translational modifications (Bononi et al., 2011). 
3.1 AKT kinase 
 The serine/threonine kinase AKT represents an important connection in 
diverse signaling cascades downstream of growth factor receptor tyrosine 
kinases, and other cellular stimuli. AKT plays an essential role in cell survival, 
growth, proliferation, angiogenesis, metabolism, migration and self renewal of 
stem cells. Deregulation of AKT activity has been associated with cancer and 
other disease conditions, such as neurodegenerative diseases and muscle 
hypotrophy (Bononi et al., 2011). Among the downstream effectors of PI3Ks, 
AKT is the most important and best studied. The three AKT isoforms have 
extensive homology with protein kinases A, G, and C within their kinase 
domains and are, therefore, members of the AGC kinase family (Manning and 
Cantley, 2007). AKT possesses an N-terminal PH domain of approximately 
100 amino acids, similar to PH domains found in other signalling molecules 
that bind 3-phosphoinositides. It binds, with its PH domain, to both PIP3 and 
phosphatidylinositol 4,5- bisphosphate (PIP2) with similar affinity (Frech et al., 
1997). The kinase catalytic domain is located in the central region of the 
protein (Nicholson and Anderson, 2002). Finally, the C-terminal tail contains a 
second regulatory phosphorylation site. This region possesses the F-X-X-F/Y-
S/T-Y/F hydrophobic motif that is characteristic of the AGC kinase family.  
 AKT is activated through receptor tyrosine kinase pathways. Full 
activation of AKT is a multistep process, and the final step is the 
phosphorylation of AKT on two sites, Thr308 and Ser473 via PDK1 and 
PDK2, respectively. (Alessi et al., 1996). The molecular interaction between 
the phosphorylated hydrophobic motif and the cavity, formed by the αB and C-
helices, stabilizes the catalytic domain: this is very important for the complete 
activation of AKT. The activation of the PI3K signaling pathway by growth 
factor stimulation leads to recruitment of AKT to the plasma membrane 
through binding to PIP3, here, AKT can be activated by two different kinases, 
PDK1 (Stephens et al., 1998) and the mTORC2 (Sarbassov et al., 2005). Then, 
AKT is addressed to various subcellular compartments where it phosphorylates 
substrates or interacts with other molecules. Through phosphorylation, AKT 
may either positively or negatively affect the function of these substrates, alter 
their subcellular localization, or modify their protein stabilities. Depending on 
phosporylated substrates AKT leads to uncontrolled cell proliferation, inhibited 
apoptotic pathways, and strong cell cycle dysregulation, typical hallmarks of 
many human cancers.  
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Nuclear AKT has a crucial role in apoptosis as a regulator of 
transcriptional factors for the expression of pro- or anti-apoptotic molecules, 
such as: YAP, CREB, FOXO proteins, or NF-κB, and MDM2. The latter is a 
well known negative regulator of the p53. Phosphorylation of some 
transcription factors like: CREB and NF-κB induces upregulation of 
antiapoptotic Bcl-2 family members, whereas phosphorylation of other proteins 
(FOXO family members) impairs the apoptotic response (Rena et al., 1999) 
(Biggs et al., 1999). Indeed, among the several target of AKT there is Bad, a 
pro-apoptotic member of Bcl2 family. Phosphorylation of Bad on S136 by 
AKT blocks its interaction with Bcl- 2/Bcl-XL, sequestering Bad in the 
cytosol, and preventing the apoptotic response. In the same way, AKT 
phosphorylates also the pro-apoptotic Bax protein on S184, suppressing its 
translocation to mitochondria, and impairs the apoptotic response (Gardai et 
al., 2004).   
 The best known function of AKT is its role in promoting cell growth. In 
this function is involved mTORC1 complex, which is regulated by both 
nutrients and growth factor signalling. AKT has been suggested to directly 
phosphorylate mTOR on S2448 (Scott et al., 1998), but the role of this 
phosphorylation remains still unclear. In this context, this phosphorylation 
seems to be important for cell proliferation, controlling the translation of 
proteins important for cell-cycle progression.  
3.2 PTEN phosphatase 
 In the 1990s, two groups independently found a locus that is frequently 
deleted in a variety of advanced cancers, identified a new phosphatase termed 
PTEN (Li et al., 1997). This locus appears to be the second most frequently 
mutated tumor-suppressor gene in human cancers after p53(Chalhoub and 
Baker, 2009). Today, it is well documented that PTEN is involved in diverse 
cellular processes such as cell-cycle progression, cell proliferation, apoptosis, 
ageing, DNA damage response, angiogenesis, muscle contractility, chemotaxis, 
cell polarity, and stem cell maintenance.  
 The human PTEN gene is made up of 9 exons and codes for a 403-
amino-acid protein. This protein is characterized by five functional domains: a 
short N-terminal PIP2-binding domain, a phosphatase domain, a C2 domain, a 
C-terminal tail containing PEST (proline, glutamic acid, serine, threonine) 
sequences, and a PDZ interaction motif (Chalhoub and Baker, 2009). As its 
name suggests, the PTEN is a dual-specific phosphatases and it is able to 
remov phosphates from protein and lipid substrates. PTEN has the Cys-X5-
Arg-Thr/Ser (CX5RT/S) phosphatase catalytic signature and belongs to the 
protein tyrosine phosphatase superfamily. It has been suggested that cytosolic 
PTEN is found in an inactive conformation with the PIP2-binding domain 
masking its catalytic site, whereas binding to PIP2 at the plasma membrane 
could result in an open active conformation of the PTEN protein. PTEN acts as 
a negative regulator of the PI3K-AKT pathway by removing the phosphate 
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from the three-position of the inositol ring to generate PIP2. (Haas-Kogan et 
al., 1998). So, the loss of PTEN leads to constitutively high levels of PIP3, 
which promotes the recruitment of a subset of proteins to cellular membranes, 
including PDK1 and AKT kinase. As described above, AKT is the major 
downstream effector of PI3K signalling that can phosphorylate several 
substrates and, thus, stimulates cell growth, proliferation, and survival 
(Manning and Cantley, 2007) (Figure 4).  
3.3 JNK kinase 
 The mitogen-activated protein kinase (MAPK) signaling pathway is one 
of the major signaling systems that transduce extracellular signals into cells. 
These pathways regulate several different cellular functions such as 
proliferation, differentiation and survival. There are three major groups of 
MAPKs: the extraceullular signal-regulated kinase (ERK), the c-Jun N-
terminal kinase (JNK) and the p38 MAPKs. All of these pathways are involved 
in cancer progression. They also have a high degree of interaction and cross-
talk with the PI3K/AKT pathway (Rodriguez-Viciana et al., 1994). The second 
MAPK signaling transduction pathway (JNK pathway) is involved in cellular 
stress, apoptosis, survival, transformation and differentiation. MAPKKKs for 
the JNK pathway are stimulated by a variety of factors, primarily by cytokines 
and exposure to environmental stress. Upon stimulation, one of several 
MAPKKKs activates either one of JNK pathway’s MAPKKs (MKK4 or 
MKK7). Following JNK activation, several substrates could be phosphorylated 
(ATF2, c-Myc, p53, Paxilin); however, a major target of the JNK signaling 
pathway is the activation of AP-1 transcription factor that is
 13 
 
 
 
 
 
 
Figure 4: PI3K signalling pathway. 
 The phosphatidylinositol 3-kinase (PI3K) signaling pathway starts with the 
binding of growth factors to receptor tyrosine kinases. This biding activates PI3K. 
After, PI3K phosphorylates the lipid second messenger PIP2 (indicated by red 
phosphoinositide) in PIP3 (indicated by green phosphoinositide. This leads to the 
recruitment of AKT on the plasma membrane, where it is phosporylated for its 
activation. Then, AKT favors cell proliferation and survival by regulation of several 
pro-apoptotic targets (hold by the red dotted line), or by activation of mTOR complex 
1. AKT is inhibited by protein phosphatase 2a (PP2a) family, favoring apoptosis, or by 
the tumor suppressor phosphatase PTEN, which dephosphorylated PIP3, converting it 
back to PIP2. (Bononi et al., 2011). 
 
 
mediated by the phosphorylation of c-Jun and related transcription factor that is 
mediated by the phosphorylation of c-Jun and related molecules (Weston and 
Davis, 2002). Finally, these transduction signals activated target genes 
controlling cell cycle, proliferation, differentiation as well as death. Like other 
pathways, JNK controls the apoptotic response by balancing the expression 
levels of proteins such as Bcl-2, Bad, Bax. There is the possibility of the 
existence of a feedback loop between the AKT and JNK pathways. In response 
to various proapoptotic stimuli, many pathways including AKT can inhibit 
JNK to promote cell survival. Indeed, AKT substrates and ASK1 have a similar 
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sequence, so ASK is an upstream regulator of the JNK pathway. This promotes 
apoptosis and activates the next component in the JNK pathway. One study has 
shown that AKT can phosphorylate ASK1 at Ser83 residue, thereby, inhibiting 
ASK1 and leading to blockade of apoptosis and promoting cell 
survival(Jazirehi et al., 2012). Furthermore, AKT and JNK share the same 
substrate, that is FOXO3A, which is involved in the activation of the apoptotic 
response.   
3.4 Fe65 in the cellular response to DNA damage 
 Several experimental data have shown that chromatin remodeling, in 
the region surrounding the damaged DNA site, is a key event for the success of 
the cellular response to DNA damage. The chromatin remodeling involves a 
series of post-translational modifications on the amino-terminal tail of histones 
of the nucleosome, in particular H3 and H4. It has been shown that in the 
remodeling associated with DNA damage repair, the main changes involve the 
acetylation of histone H4 by the NuA4 complex containing the histone 
acetyltransferase Tip60 (interactor of Fe65) and its cofactor TRRAP, which are 
rapidly recruited to double strand breaks (DSBs) (Bird et al., 2002). Tip60 has 
a key role in the response to DNA damage and it can affect tumorigenesis in 
different ways. First, Tip60 is a co-regulator of transcription factors that either 
promote or suppress tumorigenesis, such as Myc and p53. Furthermore, it has 
an important role in response to DNA damage triggered by oncogenes. This 
leads to the conclusion that Tip60 is a tumor suppressor required in response to 
DNA damage induced by oncogene (Gorrini et al., 2007). The interaction 
between Fe65 and Tip60 has suggested that also Fe65 is involved in the DNA 
damage response. Indeed, the study of the phenotype of Fe65 null mice led to 
the observation that these mice are more sensitive to DNA-damaging 
agents(Minopoli et al., 2007) and, similarly, wild-type mouse embryo 
fibroblasts (MEFs), treated with low doses of etoposide or H2O2, have only 
marginal effects compared to knock-out MEFs that have high levels of DNA 
damage and accumulation of γ-H2AX. Same results were obtained in NIH3T3 
and N2A cells where the Fe65 expression was silenced by RNA interference. 
This phenotype depends on the presence of Fe65 in the nucleus. Indeed, the 
phenotype of increased sensitivity to DNA damage cell knock-out is recovered 
by the expression of proteins wild-type but not by a protein Fe65 fused with a 
nuclear export signal, unable to remain in the nucleus(Minopoli et al., 2007). 
These observations have suggested the possibility that Fe65 is a protein that 
binds chromatin. Indeed, studies of chromatin immunoprecipitation with 
histone H3 at the genomic level and global analysis of the accessibility of 
chromatin to digestion by micrococcal nuclease in cells wild-type and knock-
out or knock-down for Fe65, showed that in the chromatin is more relaxed than 
in wild-type.  
The molecular basis of the phenotypes observed in cells knock-
out/knock-down for Fe65, after DNA damage, is still not completely 
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understood. This increased sensitivity seems to be dependent, at least in vitro, 
on a defective DNA damage repair, due to a decreased recruitment of 
Tip60/TRAPP complex at DNA double strand breaks and in turn the 
acetylation of histone H4 in cells Fe65 knock-out and knock-down. This 
phenotype depends from Fe65 and Tip60 interaction although it is rescued by 
Fe65 full-length but not by Fe65 ∆-PTB1 mutant, unable to interact with 
Tip60. Furthermore, Fe65 is subjected to rapid phosphorylation upon DNA 
damage, suggesting that phosphorylation could be the triggering mechanism 
for the correct localization of the complex NuA4.  
 Several data suggest that the cleavage by the γ-secretase is necessary 
for the nuclear localization of Fe65-AICD. Indeed, in cells treated with 
etoposide APP maturation by the γ-secretase was observed, and that this 
maturation is dependent on the changes of Fe65 induced by genotoxic stress. 
So, the interaction APP / AICD is necessary to allow proper function of Fe65 
during the repair, as it allows the association of Fe65 with chromatin. Indeed, 
the interaction of Fe65 with APP induces a conformational change leading 
Fe65 from a ‘‘closed’’ to an ‘‘open’’ conformation, allowing Fe65 to acquire 
the most appropriate form for the response to DNA damage. Another 
interesting possibility is that Fe65, bound to APP cytodomain and thus in its 
‘‘open’’ active conformation, is released from APP as a consequence of APP 
phosphorylation at Thr668, possibly catalyzed by c-Jun N-terminal kinase JNK 
(Taru and Suzuki, 2004) (Figure 5). Nuclear Fe65 is then rapidly modified, 
likely phosphorylated, and it is necessary for Tip60 recruitment at the DNA 
breaks. Further results were obtained by studying of APP and APLP2 knock-
down, in which there isn’t the recruitment of Tip60 and, therefore, the 
acetylation of histone H4, as Fe65 is not bound to chromatin (Stante et al., 
2009). In conclusion, in the native chromatin Fe65 favors the packing of 
chromatin, whereas DNA DSBs, stimulates the recruitment of Tip60, 
acetylation of histone H4 and the local relaxation of chromatin. 
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Figure 5: The Fe65–Tip60 complex in the DNA repair mechanisms. 
 Available results support the hypothesis that Fe65 exists in two 
conformations. The interaction with the cytodomain of APP induces Fe65 from a 
“close” to an “open” conformation. The cleavage of APP or its phosphorylation may 
cause the release of Fe65 from the membrane anchor thus allowing its association with 
chromatin. In basal conditions, chromatinized Fe65 appears to have a general role in 
favoring chromatin condensation. Chromatin associated Fe65 is necessary for the 
recruitment of Tip60-TRRAP-containing complex at DNA double strand breaks. Loss 
of function of the Fe65-APP machinery induces a significant decrease of DNA repair 
efficiency (Minopoli et al., 2012).  
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Aims of the study  
 The possible involvement of Fe65 in the DDR, suggested us to explore 
whether it has any role in transformation. To this aim I investigated the role of 
Fe65 in the apoptotic response of the cells to genotoxic stress and to oncogene 
activation. Furthermore, I observed that Fe65 behaves as a tumor suppressor 
gene, promoting oncogene-induced transformation in vitro and in vivo.  
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Materials and Methods 
1 Mouse embryo fibroblasts (MEFs) isolation and 
cell culture  
 Primary MEFs were isolated from Fe65+/+, Fe65+/- and Fe65-/- 
embryos, obtained by crossing Fe65+/+ x Fe65+/+, Fe65+/+ x Fe65-/-, and 
Fe65-/- x Fe65-/- mice, respectively. Embryos were collected at day 13.5 p.c. 
and, after removal of head and internal organs, minced and trypsinized. Cell 
suspension was centrifuged at 1100 rpm for 5 minutes and then plated in a 100 
mm dish containing DMEM (Sigma-Aldrich, Saint-Louis, MO, USA), 10% 
fetal bovine serum (FBS; Hyclone, Watham, MA, USA), 2 mM glutamine 
(Lonza, Basel, Switzerland), 100 U/ml penicillin (Invitrogen, Carlsbad, CA, 
USA), 100 µg/ml streptomycin (Invitrogen) and incubated at 37°C in 5% CO2. 
The cells were routinely passaged just before reaching confluence. Unless 
otherwise specified, experiments were performed on MEFs at passage 2. The 
samples Fe65 +/+ represent one pool of three different wild-type embryos. The 
same is for Fe65 +/- and Fe65 -/- samples. 
 NIH 3T3 cells were cultured in DMEM supplemented with 10% FBS, 2 mM 
glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin 
Proliferation Fe65 -/- MEFs was assayed by doubling time experiments: 
10 x 104 cells were seeded in 60mm dish, and viable cells counted at various 
time points up to 7 days with trypan blue. MEFs were irradiated with 1 or 5 or 
15 Gy of X rays, as indicated, by using RS2000 Biological Irradiator (Rad 
Source, Suwanee, GA, USA) or with 30 J/m-2 by using UV Stratalinker 1800 
(Stratagene, La Jolla, CA, USA) and incubated for indicated times before 
analysis. Apoptotic cells were measured by TUNEL assays kit (Millipore, 
Billerica, MA, USA) following the manufacturer’s instructions.  
 
2 Cell cycle analysis 
 Cell cycle entry experiments were performed on asynchronous cells, 
starved cells and irradiated cells. They were plated in 100 mm dishes and 
grown up to passage 2. Confluence-arrested cells were starved in medium 
without serum for 72 h and then stimulated with medium containing 10% FBS. 
To monitor entry into the cell cycle, cells were harvested at specific time 
points, washed three times with PBS, resuspended in PBS containing 0.02 
mg/ml propidium iodide (Sigma), 0.004% NP40 (Sigma) and 0.5 mg/ml 
DNase-free RNase (Applichem GmbH, Darmstadt, Germany) and analyzed by 
FACS using a FACScanto (BD Biosciences, San Jose, CA, USA) instrument. 
Exponentially growing cells were exposed to 1 Gy of X rays and analyzed after 
24 hours.  
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3 Retroviral infections 
 Retroviruses were prepared by transfecting the Platinum-E ecotropic 
packaging cell line (Cell Biolabs Inc., San Diego, CA, USA) with pMXs-c-
Myc (32, Addgene plasmid 13375) and/or pLZRS-RasV12 (33, Addgene 
Plasmid 21203) or pLZRS-EGFP vectors with Lipofectamine 2000 
(Invitrogen) following the manufacturer’s instructions. 24 hours after 
transfection, medium was replaced and virus-containing supernatants from 
transfected Plat E cells were collected after further 24 hours. MEFs (5 x105 / 
100 mm dish) were infected with control EGFP virus, c-Myc virus alone or c-
Myc plus RasV12 in the presence of 4 mg/ml polybrene (Sigma) for 14-16 
hours at 37°C. After replacement of viral supernatants with fresh culture 
medium, MEFs were incubated at 37°C for additional 48 hours. For c-Myc 
plus RasV12 infections, MEFs were infected sequentially with c-Myc virus 
first and 48 hours later with RasV12 virus. Parallel infections with EGFP 
expressing virus were used to determine the infection efficiency. 
 
4 PCR and Quantitative RT-PCR 
 For genotyping, genomic DNA was extracted with Qiagen Gentra 
Puregene Kit (Qiagen, Hilden, Germany) following the manufacturer’s 
procedures. The oligonucleotide primers used for amplifications are reported in 
Table 1.   
Table 1: Oligonucleotides used for mice genotyping 
mFe65 Intr1 forward 5’-TGGTGTTTGCTGGCTTACTGA-3’ 
neo up forward 5’-TGCGGTGGGCTCTATGGCTTCTG-3’ 
mFe65 Ex2 reverse  5’-CTCCTCCTCCTCTTCGTCTTC-3’ 
 
Fe65 exons were amplified with oligonucleotide primers indicated in Table 2.  
Table 2: Oligonucleotide primers for mouse and human Fe65 gene 
analysis 
 Primer Forward 
mFe65 ex 9 for 5’-GACTTTGCCTACGTAGCTCGAGA-3’ 
mFe65 ex 10 rev 5’-TGGAAAGGGACATCCACGAGT-3’ 
hFe65 ex 2 for 5’- GAGCTGCCAAGGCCATGT-3’ 
hFe65 ex 2 rev 5’-AGAGTACAGGTGTATCAGGCCTTT-3’ 
hFe65 ex 3 for 5’-TTCTGGAACCCCAACGCCT-3’ 
hFe65 ex 5 rev 
 
5’-CTGAGGCTCTGAGCTGGGAA-3’ 
 hFe65 ex 9 for 
 
5’-GCCTACGTAGCTCGTGATAAGCT-3’ 
 hFe65 ex 10 rev 
 
5’-CTTGGAAAGGGACATCCACAAGTTT-3’ 
 hFe65 ex 12 for 
 
5’-ATGTGATTAATGGGGCCCTCGA-3’ 
 hFe65 ex 13 rev 
 
5’-TCTGAGAGGCTGGCAGCATT-3’ 
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Total RNA was purified from MEFs using the TRl reagent (Sigma) and the 
cDNA was prepared with M-MLV RT, following manufacturer’s instructions 
(New England Biolabs, Ipswitch, MA, USA). Real-time RT-PCR was carried 
out on an ABI PRISM 7900HT Sequence Detection System (Applied 
Biosystems, Foster City, CA, USA) using Power SYBR Green PCR Master 
mix (Applied Biosystems). The GAPDH mRNA was used to normalize the 
samples. Gene-specific primers are reported in Table 2. 
 
Table 2: Oligonucleotides used for quantitative Real Time PCR 
xperiments 
 Primer Forward Primer Reverse 
mGapdh 5’-GTATGACTCCACTCACGGCAAA-3’ 5’-TTCCCATTCTCGGCCTTG-3’ 
mBax 5’-ACAGATCATGAAGACAGGGG-3’ 5’-CAAAGTAGAAGAGGGCAACC-3’ 
mPuma 5’-ATGGCGGACGACCTCAAC-3’ 5’-AGTCATGAAGAGATTGTACATGAC-3’ 
mFe65 5’-CCTCCTTCTGCTGTCACATGTTT-3’ 5’-TTCTGGTAGCGGAGCATGC-3’ 
mp21 5’-TCAGAGTCTAGGGGAATTGGA-3’ 5’-AATCACGGCGCAACTGCT-3’ 
hFe65   5’-GGACTCAAGCTGGGCTACCT-3’ 5’-GTTGGGGTTCCAGAAGGAAT-3’ 
hGapdh 5’-GAAGATGGTGATGGGATTTC-3’ 5’-GAAGGTGAAGGTCGGAGTC-3’ 
 
 
5 Co-immunoprecipitation and Western Blot 
 MEFs were irradiated with 15 Gy of X-rays and, after 30 min; nuclear 
proteins were purified from control and irradiated cells as previously 
described(Minopoli et al., 2007). 1 mg of each nuclear extract was precleared 
with Protein A/G plus agarose beads (Santa Cruz Biotechnology, Santa Cruz, 
CA, USA). Cleared supernatants were incubated with 3 µg of γH2A.X 
antibody (Millipore) or with 3 µg of mouse IgG (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) overnight at 4°C. Immunoprecipitated proteins were 
analyzed by western blot with JNK antibody (Santa Cruz Biotechnology). The 
antibodies used for western blot experiments are: AKT, phospho-S473 AKT, 
phospho-S15 p53 and phospho-(T183, Y185) JNK (Cell Signaling, Danvers, 
MA, USA), PTEN (Abcam, Cambridge, UK), GAPDH (Santa Cruz 
Biotechnology), total H2A.X (Bethyl Laboratories Inc., Montgomery, TX, 
USA), β-actin (Sigma-Aldrich, Saint-Louis, MO, USA) rabbit polyclonal anti-
Fe65 ((Zambrano et al., 1997a)).  
6 Anchorage-independent growth assay 
 MEFs were mock infected or infected with c-Myc alone or with c-Myc 
plus RasV12 as described above. Twelve hours after infection 3 x 104 cells 
were suspended in DMEM containing 0,3% bacto-agar and seeded in 60 mm 
plates on a bottom layer containing 0.5% bacto-agar. 
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100000 NIH3T3 cells were seeded in 100-mm dishes, transfected by 
lipofectamine with Fe65 siRNAs pool or non-silencing siRNA (Dharmacon, 
Lafayette, CO, USA) and, 24 hours later, with pRCmv-K-Ras A59T (34) or 
pRCmv empty vector. 24h after transfection, 5x103 cells were harvested and 
seeded in 60 mm plates containing 2 ml of a 0.3% bacto-agar suspension in 
DMEM plus 10% FBS and incubated at 37°C with 5% CO2 for 4 weeks. The 
transforming efficiency was expressed as number of colonies/plate, in triplicate 
in three independent experiments.  
 
7 Bisulfite genomic sequencing (BGS) 
 Genomic DNA was extracted from frozen tissue of 3 ovary cancers and 
from a control ovary specimen with Purgene Core Kit A (Quiagen) following 
the manufacture’s instruction. 2 µg the purified DNA for each sample were 
treated with sodium bisulfite and purified by using the EpiTect Bisulfite Kit 
(Quiagen) according with the instruction of the manufacture.  200 ng of each 
converted DNA were amplified by PCR with 2,5 U of HotStarTaq DNA 
polymerase (Quiagen). Amplified DNA fragments were extracted from agarose 
by using Wizard SV Gel and PCR Clean-Up System (Promega) and cloned in 
the pGEM- T Easy Vector (Promega). 5 clones of each sample were sequenced 
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Results and discussion 
1 Fe65 suppression affects the apoptotic response 
to DNA damaging agents 
Among the events induced by genotoxic stress, apoptosis plays a crucial 
role as a natural barrier against the possible dangerous consequences of DNA 
damages. It is known that Fe65 -/- MEFs are more sensitive to genotoxic stress 
than wild-type counterparts so, I observed whether Fe65 suppression affects 
the apoptotic response of the cells to DNA damage. To this aim, Fe65-/- mouse 
embryo fibroblasts (MEFs) Fe65 +/- and the wt counterpart were obtained from 
E13.5 embryos and used in all the experiments at passage 2. In the experiments 
reported in figure 1, I checked the expression of Fe65 in MEFs for both mRNA 
(panel A) and protein (panel B), and I observed a strong decrease of Fe65 
expression in Fe 65 -/- MEFs.  
 
 
              
Figure 1: Fe65 mRNA and protein levels in wt and mutant MEFs 
 (A) Q-PCR analysis of RNA from wt, Fe65+/- and Fe65-/- MEFs. (B) 
Western blot analysis of extracts from wt, Fe65+/- and Fe65-/- MEFs with Fe65 
polyclonal antibody. 
  
 
The first experiment, that I performed on this cell, was the Tunel Assay. This is 
a method for detecting DNA fragmentation that results from apoptotic 
signaling cascades by labeling the terminal end of nucleic acids. 
The assay relies on the presence of nicks in the DNA which can be identified 
by terminal deoxynucleotidyl transferase or TdT, an enzyme that will 
catalyze the addition of dUTPs that are secondarily labeled with a marker. For 
this purpose  Fe65 +/+ and Fe65 -/- MEFs were irradiated with 15 Gy of X-
rays. As shown in Figure 2 Fe65 -/- MEFs don’t activate the apoptotic response 
because there are a little number of cells undergoing apoptosis, compared to 
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wt. Very similar results were obtained by exposing the cells to 30 J/sqm of UV 
rays.  
 
 
                           
                                                                
              
 
 
 
Figure 2: Fe65 suppression hampers apoptotic response to DNA damage  
   Fe65-/- and wt MEFs were exposed to 15 Gy of X rays (IR) or to 30 J/sqm of 
UV rays (UV). 16 hours after the exposure, the cells were fixed and apoptotic cells 
analyzed by TUNEL assay. Apoptotic cells are reported as percentage of total cell. 
Histograms report the mean values of three independent experiments. Each MEF 
preparation consists in a pool of at least three distinct embryos. Representative 
examples of DAPI (blue) and TUNEL (green) staining are shown (scale bar= 50 mm). 
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1.1 The oncogene-induced apoptosis is hampered 
in Fe65 KO MEFs 
The apoptotic response to genotoxic stress is also induced by oncogenes. 
Indeed, the constitutive expression of c-Myc induces MEFs to undergo 
apoptosis, thus failing to transform primary mouse fibroblasts, whereas the 
contemporary expression of c-Myc and oncogenic Ras is needed to induce 
transformation. Therefore, wt, Fe65 +/- and Fe65-/- MEFs were infected with 
the virus driving the expression of c-Myc with or without the virus driving the 
expression of H-RasV12. As shown in Figure 3, the expression of c-Myc alone 
induced, as expected, the wt MEFs to undergo apoptosis, while no apoptosis 
was seen in these cells when infected with c-Myc plus oncogenic Ras. On the 
contrary, Fe65-/- cells infected with c-Myc alone didn’t show an induction of 
apoptosis, thus indicating that the absence of Fe65 affects the apoptotic 
response of MEFs to genotoxic stress induced by c-Myc. 
 
         
 
 
           
 
Figure 3: Apoptotic response induced by oncogene in Fe65 KO MEFs 
Fe65-/-, Fe65+/- and wt MEFs were infected with Myc alone or with Myc and 
RasV12 vectors. 48 hours after the infection cells undergoing apoptosis were analyzed 
by TUNEL as in panel A. Error bars represent S.D.. The asterisks indicate a 
significant difference with a p<0.001. Representative examples of DAPI (blue) and 
TUNEL (green) staining of Myc transfected cells are shown (scale bar= 50 mm). 
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2 Altered proliferative behavior of Fe65-/- MEFs 
Cellular Myc levels have profound consequences on cell proliferation; because 
I observed that the overexpression of Myc doesn’t induce the apoptotic 
response in Fe65 -/- MEFs, I decided to investigate whether cell proliferation 
was affected by loss of Fe65 in MEFs. To this aim Fe65 +/+, Fe65 +/- and 
Fe65 -/- were plated at 105 cells/60 mm dish at day 0 and counted every 24 
hours for a week. As shown in figure 4 Fe65-/- MEFs showed a growth rate 
higher than that observed in wt cells, whereas Fe65 +/- MEFs have a 
phenotype similar to that of Fe65+/+ MEFs. This observation was confirmed in 
three cell preparations from different embryos of each genotype. 
 
 
              
  
 
Figure 4: Fe65 suppression enhances proliferation of primary MEFs 
 Passage 2 MEFs, wt (+/+), Fe65+/- or Fe65-/-, from three distinct pools of at 
least three embryos each, were plated at 100 000 cells/60 mm dish at day 0, and 
counted at the indicated times. Error bars represent S.D.. The asterisks indicate 
significant differences with p< 0.01. 
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2.1 Fe65 knock down (KD) cells have the same 
phenotype of KO MEFs  
 To confirm the phenotype observed in Fe65 KO MEFs we analyzed the 
cell proliferation in other cellular systems in which Fe65 knockdown was 
obtained by RNA interference strategy. In NIH3T3 cells Fe65 expression was 
transiently suppressed by transfecting a siRNA targeting Fe65. A non silencing 
(ns) siRNA was transfected in control cells. As shown in figure 3A the western 
blot analysis with a specific Fe65 antibody, revealed that Fe65 protein level 
was reduced of about 80% compared to non silencing transfected cells. After 
24 h these cells were plated as in figure 4 and counted every 12 hours for 3 
days. As shown in the graph (Figure 5), Fe65 silencing in NIH3T3 cells 
resulted in a significant increase of the growth rate, similar to what observed in 
Fe65 KO MEFs.  
 
                
 
 
Figure 5: Suppression of Fe65 by RNA interference results in the same 
phenotype observed in Fe65 KO MEFs  
 NIH3T3 cells were transfected with with non-silencing (NS) or Fe65 targeting 
siRNAs. Western blot analysis demonstrated that the decrease of Fe65 levels due to 
RNAi was of about 80%, compared to cells transfected with non silencing (ns) siRNA. 
After 24h these cells were plated at 105 cells/60 mm dish at day 0 and counted every 
12 hours for 3 days. Error bars represent S.D.. The asterisks indicate significant 
differences with p< 0.01. 
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2.2 Fe65 suppression affects the cell cycle control 
 To understand the mechanism of cell proliferation phenotype I 
examined the effects of Fe65 suppression on cell cycle progression using flow 
cytometry. This method allows to distinguish cells in different phases of 
the cell cycle. The fluorescence intensity of the stained cells at certain 
wavelengths will therefore correlate with the amount of DNA they contain. As 
the DNA content of cells duplicates during the S phase of the cell cycle, the 
relative amount of cells in the G0 phase and G1phase (before S phase), in the S 
phase, and in the G2 phase and M phase (after S phase) can be determined, as 
the fluorescence of cells in the G2/M phase will be twice as high as that of cells 
in the G0/G1 phase. The analysis of the cell cycle progression upon serum 
stimulation showed that Fe65-/- MEFs enter S-phase before wild-type and 
heterozygous cells, as demonstrated in figure 6, by FACS profiles of propidium 
iodide stained MEFs at various times after serum stimulation for 48 hours of 
serum starved cells. I observed an altered control of cell cycle in Fe65 KO cells 
also in exponentially growing cells. Indeed, Fe65-/- cells showed an increased 
percentage of cells in G2-M phases compared to wt and heterozygous cells and 
a reduced number of cells in S phase. Furthermore, when Fe65-/- cells were 
irradiated with 1 Gy of X rays they showed a defective arrest of the cell cycle, 
compared to wt cells that, on the contrary, responded to the damage with a G1 
arrest (Figure 6B).  
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Figure 6: Altered cell cycle kinetics in Fe65-/- MEFs. 
 A. Cell cycle re-entry after 72-hour serum starvation was analyzed by FACS 
profiling of propidium iodide (PI) stained cells. Histograms report the percentage of 
cells in G1, S and G2/M phases of the cell cycle at time 0, 24 and 48 hours after the 
exposure to 10% FBS. B. Exponentially growing cells at 70% confluence were 
exposed or not to 1 Gy of X rays (IR). 24 hours after the irradiation, the cells were 
stained with PI and analyzed by FACS as in panel A. Error bars represent S.D.. The 
asterisks indicate significant differences with p<0.01. 
 
It is well know that p21 induction, by p53, blocks cell cycle and increases the 
apoptosis. So, I investigated whether p21 is involved in defective arrest of cell 
cycle in Fe65 -/- MEFs. To this aim, MEFs were irradiated with a letal dose of 
X-Rays and were harvested 16 hours after irradiation. As shown in figure 7, 
Fe65 -/- MEFs lack the induction of p21 following DNA damage. 
                               
Figure 7: UV not induced p21 activation in Fe65 -/- MEFs 
 MEFs were irradiated with 30 J/sqm of UV rays and harvested 16 hours after 
irradiation. Expression of p21 in mRNA samples was analyzed by Q-PCR. Error bars 
represent S.D.. The asterisks indicate significant differences with p<0.01. 
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3 Fe65 deficiency favors oncogenic 
transformation in vitro 
 The phenotypes of Fe65 suppression on the induction of apoptosis and 
on cell proliferation could obviously have relevant effects on cell 
transformation. Early passage primary fibroblasts are poorly susceptible to 
oncogenic transformation, so, I tested whether Fe65 KO has any effects on the 
ability of Myc and oncogenic H-RasV12 to transforms MEFs. To this aim, I 
performed an anchorage-independent growth assay in soft agar. This assay is a 
common method to monitor anchorage-independent growth, which measures 
proliferation in a semisolid culture media after 3-4 weeks by manual counting 
of colonies. It is one of the hallmarks of cell transformation, because is 
considered the most accurate and stringent in vitro assay for detecting 
malignant transformation of cells. MEFs Fe65 +/+ and Fe65 -/- were infected 
with a viral vectors driving the expression of Myc and/or RasV12. Then the 
cells were plated on soft agar. As shown in Figure 8A, Myc alone had very 
little effect on cell transformation in wild type MEFs. On the contrary, c-Myc 
was able to induce the growth of a significant number of colonies of Fe65-/- 
cells. Also the contemporary expression of both Myc and H-RasV12 induced a 
significant higher number of colonies in KO than in WT cells, thus indicating 
that the suppression of Fe65 sensitizes primary fibroblasts to transformation. 
Then, I examined whether Fe65 suppression by RNA interference may favor 
the appearance of the transformed phenotype induced by mutant Ras 
transfection also in NIH3T3. In this assay, NIH3T3 cells were transfecetd with 
K-Ras A59T or with an empty vector and the resulting colonies were counted 
21 days after transfection. The results of figure 8B indicated that the silencing 
of Fe65 by RNAi significantly increased the number of the colonies and also 
their main size. Taken together these results indicate that Fe65 behaves in 
primary MEFs and in NHI3T3 cells as a tumor suppressor, as its 
downregulation favors the transformation induced by c-Myc and/or by mutant 
Ras. 
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Figure 8: Fe65-/- MEFs and Fe65 KD NIH3T3 cells are sensitive to 
oncogenes-induced transformation 
A. Passage 2 MEFs from wt (+/+) or Fe65 KO (-/-) MEFs were infected with 
empty virus (mock) or with viral vectors driving the expression of Myc and/or 
RasV12. 16 hours after the infection, 30 000 cells were plated in 60 mm dishes in soft 
agar-containing medium. Colonies growing in soft agar were counted after 21 days of 
culture. B. Effects of Fe65 suppression on NIH3T3 cells transformation by K-Ras 
A59T. NIH3T3 were transfected either with non-silencing (NS) or Fe65 targeting 
siRNAs. After 24 hours the cells were transfected with an empty vector or with a 
vector encoding RasT59. They were than plated and analyzed as in panel A. The 
extent of Fe65 silencing and Ras overexpression is reported in the western blot in 
panel B on the right. Histograms represent the mean values of colonies per plate of 
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three independent experiments. Error bars represent S.D.. Representative fields of the 
plates are shown (scale bar= 500 mm).   
 
3.1 Fe65 expression levels are decreased in 
various human lymphoma and ovary cancers 
 The results obtained in Fe65-/- MEFs and in NIH3T3 cells suggest the 
possibility that Fe65 may function as a tumor suppressor gene. So, I decide to 
first examine the expression of Fe65 in transformed cell culture. I found that in 
NIH3T3 cell line transformed in vitro by mutant K-Ras, the expression of Fe65 
was down-regulated. As shown in figure 9A, the amount of Fe65 mRNA 
present in NIH3T3 transformed cells is significantly decreased compared to wt 
cells. This downregulation is paralleled by an almost complete disappearance 
of Fe65 protein in NIH3T3 K-Ras cells (Figure 9B), thus suggesting that the 
dramatic decrease of the protein could be due also to post-translation events. 
 
 
 
 
 
                              
 
 
 
 
 
Figure 9: Fe65 in K-Ras transformed cells 
A.Fe65 mRNA levels in normal and in a NIH3T3 cell line transformed with 
K-Ras. B. Fe65 protein levels in K-Ras transformed cells and in normal counterparts. 
Error bars represent S.D.. 
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Then, I measured Fe65 expression in human lymphoma and ovary cancers by 
Q-PCR, and I observed low levels of Fe65 in many cases (Figure 10).  
 
 
                             
 
 
                         
 
 
 
 
Figure 10: Fe65 mRNA levels in human tumors 
 Boxplot distribution of Fe65 mRNA levels in ovary (n. 25) cancers and 
lymphoma (n. 19). Corresponding normal tissue were: ovary (n. 6) and reactive lymph 
node (n. 9). Values of Fe65 mRNA are relative to GAPDH mRNA levels in the same 
samples. Real-time PCR were performed in triplicate for each samples.  
 
 
 
 
Fe65 down-regulation in cancer cells could be due to gene deletion or 
rearrangements or promoter methylation. To this aim, I checked the presence 
of deletions in Fe65 gene in normal and ovary tumors samples by PCR (Figure 
11A). Then, I assayed Fe65 promoter methylation in normal and cancer ovary 
(Figure 11B). None of such modifications were observed in several cases of 
ovary cancer where Fe65 mRNA was undetectable. 
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Figure 11: Fe65 suppression in lymphoma and ovary tumors could be due 
to gene deletion or promoter methylation 
A. Genomic sequences of Fe65 gene are intact in human ovary cancers. 
Genomic DNA was amplified by using four oligonucleotides pairs to examine the 
integrity of exons 2, 3-5, 9, 10, 12-13. B. Bisulfite genomic sequencing of the 
promoter region of the human Fe65 gene from nt. 1122 to nt. -187. Open and closed 
circles indicate unmethylated and methylated CpG islands. One normal ovary and 
three ovary cancers were analyzed sequencing 5 independent clones. 
 
 
4 The apoptotic response of the cells to genotoxic 
stress is altered in Fe65-/- MEFs 
To investigate the mechanisms underlying the effects of Fe65 suppression we 
analyzed the status of several pathways that play crucial roles in the apoptotic 
response to DNA damage and in the regulation of cell proliferation. All the 
experiments reported above were made in MEFs at passage 2 and that these 
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experiments were performed in at least two different pools of MEFs from three 
distinct embryos. In this way the possibility of an in vitro selection of mutant 
cells bearing additional genetic defects targeting tumor suppressor genes 
appears to be unlikely. The best-characterized pathway opposing to Myc-
induced transformation depends on the activation of p53, which induces the 
apoptotic response by transcriptional activation of pro-apoptotic members of 
Bcl-2 family. To this aim, I irradiated Fe65 +/+, Fe65 +/- and Fe65 -/- MEFs 
with 30 J/sqm of UV rays, after 4 hours the cells were harvested and extracted 
the protein. Then, I analyzed the activation of p53 by Western Blot using an 
antibody against the serine 15 phosphorylated of p53. As shown in Figure 12A, 
p53 phosphorylation upon DNA damage is similar in all the three Fe65 
genotypes examined. However, when I looked at the effectors downstream of 
p53, I observed that Fe65-/- MEFs failed to accumulate BAX and PUMA 
mRNAs, upon DNA damage (Figure 12B, 12C). 
                                    
                                  
Figure 12: Pro-apoptotic pathway is altered in Fe65 -/- MEFs 
 A. Phospho-S15 p53 western blot analysis of MEF pools, from at least three 
independent embryos with the three genotypes, 4 hours after the exposure to 30 J/sqm 
of UV rays. B and C. Q-PCR analysis of BAX (B) and PUMA (C) mRNAs from 
untreated cells and UV-treated MEFs. mRNA samples for cDNA preparation were 
from cells harvested 16 hours after irradiation. Histograms represent the mean values 
of three independent experiments. Error bars represent S.D. Asterisks indicate 
significant differences with p< 0.01.  
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This observation is in agreement with the finding that Fe65-/- MEFs fail to 
undergo apoptosis (Fig. 2 and 3) when exposed to genotoxic stress. The nuclear 
translocation of FOXO3A is necessary to the transcription of pro-apoptotic 
genes, this mechanism is under the control of AKT. Indeed, the pro-survival 
effects of this kinase also depend on the inhibition of FOXO3A induction. So 
we examined the AKT status in Fe65-/- MEFs. To this purpose MEFs were 
irradiated with 5 Gy of X-Rays; 4 hours after irradiation the cells were 
harvested and protein extracts were prepared. Activated AKT was analyzed by 
Western Blot analysis. In these cells, I observed that basal levels of the 
phosphorylated form of this kinase are robustly increased when Fe65 is 
suppressed (Figure 13A). It is well known that PTEN inhibits the PI3P 
pathway that actives AKT. So, I investigated PTEN expression and I observed 
that the increase of AKT phosphorylation is accompanied by a slight decrease 
of the amount of PTEN in Fe65-/- MEFs (Figure 13B), which was always 
observed in all the MEFs isolated from several different embryos.  
 
                            
Figure 13: pro-survival pathways are altered in Fe65-/- MEFs 
 MEFs were irradiated with 5 Gy of X-Rays and harvested after 4 hours. 
Western blot analysis of phospho-S473 AKT and total AKT (A) and of PTEN (B). 
Each lane contains the extracts from a MEF pool from three distinct embryos.  
 
 
A possible explanation of the phenotype observed in Fe65-/- MEFs could be 
based on the recent demonstration that the silencing of Fe65 results in the 
abolishment of the recruitment of JNK1 to Y142 phosphorylated H2A.X and 
that this event hampers the apoptotic response of the cells to DNA damage 
(Cook et al., 2009). Therefore, the resistance to apoptosis in Fe65-/- MEFs 
A 
B 
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could be also due to the absence of Fe65 on the JNK/γ-H2A.X interaction. So, 
I investigated whether, in Fe65-/- MEFs exposed to IR, the recruitment of 
JNK1 to γ-H2A.X is affected. To this purpose, MEFs were irradiated, JNK1 
and γ-H2AX were co-immunoprecipitated and analyzed by Western Blot. As 
shown in Fig. 14A, JNK1 and γ-H2A.X co-immunoprecipitated in wild-type 
MEFs but not in Fe65-/- MEFs. Furthermore, I checked the basal expression of 
activated JNK and I observed that the suppression of Fe65 was also associated 
with reduced basal levels of phosphorylated JNK (Figure 13B). Therefore, the 
resistance to apoptosis we observed in Fe65-/- MEFs could be, at least in part, 
a consequence of the reduced recruitment/activation of JNK at DNA lesions 
occupied by γ-H2A.X.  
 
                   
 
                             
      
Figure 13: The absence of Fe65 prevents the recruitment of JNK to γ-
H2A.X. 
 A. Nuclear extracts from irradiated (15 Gy of X-rays) wild-type or Fe65-/- 
MEF pools were prepared 30’ after irradiation and immunoprecipitated with phospho-
S139 H2A.X antibody or control mouse IgG. Western blot analysis of co-
immunoprecipitated proteins with JNK antibody. The latter was used to assess the 
levels of JNK in nuclear extracts (on the right); H2A.X was used as loading control. B. 
Western blot analysis of total extracts from distinct MEF pools with the phospho-
(T183, Y185) JNK antibody; GAPDH was used as loading control.  
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5 Discussion 
This study demonstrates that Fe65 suppression is associated with the inhibition 
of the apoptotic response of primary MEFs to IR and UV rays or to oncogenes. 
This phenotype is associated with an increased susceptibility of Fe65-/- MEFs 
to oncogenes-induced transformation. Accordingly, we have found that human 
lymphoma and ovary tumors have reduced levels of Fe65. These data indicate 
that Fe65 has the characteristics of a tumor suppressor gene.  
The phenotype of Fe65 KO cells and mice observed before my PhD 
project suggested us to explore the possible link between the function of this 
protein and the cellular machinery devoted to protect from and/or respond to 
DNA damages. Previous results suggested that Fe65 could have some nuclear 
functions, considering its presence in the nucleus and its interaction with 
several nuclear proteins. These results supported the hypothesis that Fe65 
could be involved in the regulation of transcription, although most of them rely 
on the use of reporter gene assays. Fe65 appears to function as a key regulator 
of signals received and integrated at the membrane by APP holoprotein which 
modulates Fe65 nuclear localization and functions. Starting from the 
observation that the absence of Fe65 results in vivo and in vitro in high 
vulnerability to DNA damaging agents we tried to understand the molecular 
mechanism involving Fe65 in the DNA damage response.  
Apoptosis, or programmed cell death, is a physiologic genetically 
encoded program that results in cell death. It plays an important role in the 
elimination of unwanted cells during development and also as a balancing 
factor in maintaining proliferate homeostasis.  
The results reported here indicate that the inhibition of apoptosis 
observed in the Fe65-/- MEFs can be due, at least in part, to the constitutive 
activation of AKT and, at the same time, to the decreased levels of active JNK. 
These regulatory enzymes influence survival/apoptosis of the cells through 
several mechanisms. Their action converges on FOXO, a transcription factor 
required for the transcription of p53 targets, like BAX and PUMA (You et al., 
2006). Indeed, AKT phosphorylates FOXO thus inhibiting its nuclear 
translocation (Brunet et al., 2002), while JNK-dependent phosphorylation of 
FOXO prevents its phosphorylation by AKT (Essers et al., 2004). On this 
basis, the constitutive activation of AKT and the contemporary failure of JNK 
activation are coherent with our observation that, despite the normal 
phosphorilation of p53, BAX and PUMA are not induced as a consequence of 
DNA damage. In addition to the apoptotic defects, we also observed a 
defective cell cycle arrest when Fe65 -/- MEFs were exposed to IR. This 
finding is in agreement with the lack of induction of p21 following DNA 
damage. Considering that the complete activation of p53 also depends on its 
acetylation by Tip60 (Tang et al., 2006) we cannot exclude that the reduced 
recruitment of Tip60 at DNA lesions, observed as a consequence of Fe65 
suppression (Stante et al., 2009), could also impair p53 acetylation and 
complete activation.  
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 An important issue regards with the mechanistic relationship between 
Fe65 suppression and the observed phenotype. It was previously shown that 
Fe65 functions as an adaptor protein required for the recruitment of JNK at the 
DNA lesions labeled by the γ-H2A.X (Cook et al., 2009). This interaction is 
crucial for the induction of the apoptotic response downstream of an unrepaired 
DNA damage. I have demonstrated that the interaction of γ-H2A.X with JNK 
is abolished in Fe65-/- MEFs, thus indicating that the altered apoptotic 
phenotype observed in these cells could depend on the failure of this 
mechanism. On the basis of available results, it is impossible to support a direct 
relationship between the lack of activation of nuclear JNK with the 
downregulation of PTEN and the constitutive activation of AKT. Of course, 
the latter could be due to mechanisms involving Fe65 but independent from 
JNK. Indeed, numerous results indicated that Fe65 could function as an adaptor 
protein with a relatively large array of possible interactors. Thus the absence, 
or reduced levels, of Fe65 could affect many different pathways.  
 The observation that the expression of Fe65 is reduced in lymphoma 
and ovary cancers opens the question of the mechanisms governing this 
downregulation. The results obtained in Fe65-/- MEFs suggest that the 
suppression of Fe65 could favor the selection of cancer cells more resistant to 
apoptosis and with a more aggressive proliferative behavior. The mechanisms 
that causes Fe65 suppression in vivo appear to act on the transcription of the 
gene because I observed a decrease of Fe65 mRNA levels. I have explored the 
integrity of the gene and methylation status of the CpG island present in the 
Fe65 gene promoter in five cases of ovary cancer where Fe65 was 
downregulated, but no gross alterations of the gene or CpG hypermethylation 
were observed compared to normal tissues. Despite the small number of cases 
examined, this result suggested that CpG hypermethylation is not the major 
cause for the downregulation.  
There are only few data on the regulation of the Fe65 gene. It has been 
previously observed that Purα and YY1 are the main transcription factors 
interacting with Fe65 promoter (Zambrano et al., 1997b). In vitro experiments 
indicated that both Purα and YY1 contribute to the activation of the 
transcription of the gene, through independent and non-cooperative 
mechanisms. Several results suggest the possibility that Purα downregulation is 
associated with malignancy and its enhanced expression results in cell cycle 
arrest and resistance to oncogenes-induced transformation (Lezon-Geyda et al., 
2001) (Stacey et al., 1999) (Barr and Johnson, 2001). All the same, YY1 is 
overexpressed in many human tumors and controls, functioning as activator or 
repressor, a large array of genes, most of which associated with cancer (Gordon 
et al., 2006). Therefore, it is plausible that the regulation of Fe65 gene by Purα 
and YY1 could have a role in its suppression during tumor progression.  
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   Conclusions 
The DNA is continuously exposed to the action of endogenous or exogenous 
genotoxic agents. However, in cells, many proteins are deputies to the 
maintenance of the integrity of the genetic material, repairing injuries through 
specific mechanisms that differ depending on the type of damage that occurs 
and on the phase of the cell cycle. The activation of the cell response to DNA 
damage is a complex phenomenon that involves many factors. All the 
alterations of the proteins involved in different repair mechanisms cause the 
accumulation of mutations within the genome compromising cell survival and 
function. 
 In this study, starting from the observation that Fe65 suppression shows 
greater sensitivity to DNA damage, I demonstrated that the loss of Fe65 is 
associated to a lower efficiency in the activation of the DDR. In particular, I 
observed a strong decrease in apoptosis activation and an altered cell cycle that 
leads a neoplastic transformation. This phenotype could be due to an 
inadequate activation of JNK pathway and a constitutive activation of AKT 
that block the apoptotic response.  
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The serine/threonine kinase GSK-3 was initially de-
scribed as a key enzyme involved in glucose metabolism,
but it is now known to regulate a wide range of biological
processes, including proliferation and apoptosis. We pre-
viously reported a transformation-dependent cell death
induced by glucose limitation in K-ras–transformed
NIH3T3. To address the mechanism of this phenomenon,
we analyzed GSK-3 regulation in these cells in conditions
of high versus low glucose availability. We found that glu-
cose depletion caused a marked inhibition of GSK-3
through posttranslational mechanisms and that this inhi-
bition was much less pronounced in normal cells. Further
inhibition of GSK-3 with lithium chloride, combined
with glucose shortage, caused specific activation of AMP-
activated protein kinase and significant suppression of
proliferation in transformed but not normal cells. The
cooperative effect of lithium and low glucose availability
on cell growth did not seem to depend exclusively on ras
pathway activation because two human cell lines, A549
and MDA-MB-231, both harboring an activated ras gene,
showed very different sensitivity to lithium. These find-
ings thus provide a rationale to further analyze the bio-
chemical bases for combined glucose deprivation and
GSK-3 inhibition as a new approach to control trans-
formed cell growth. (Am J Pathol 2011, 178:1814–1823;
DOI: 10.1016/j.ajpath.2010.12.047)
GSK-3 is a multifunctional serine/threonine kinase that
plays a major role in Wnt and Hedgehog signaling path-
ways, the regulation of cell division cycle, cell fate and
survival, stem cell renewal, apoptosis, neuronal cell
growth and differentiation, and circadian rhythm.1 In
mammals, two isoforms are encoded by distinct genes,
GSK-3 and GSK-3, that, despite a high degree of simi-
larity, are not functionally redundant.2 The protein function
of GSK-3 is much better investigated. Consistent with the
observation that GSK-3 is involved in many cellular path-
ways, its dysregulation has been implicated in various hu-
man diseases, such as bipolar mood disorder, neurode-
generative pathologic conditions, and diabetes.3
Regarding the role of GSK-3 in cancer, conflicting re-
sults are found in the literature. Oncogenic transcription
factors (eg, c-Jun and c-Myc) and proto-oncoproteins (ie,
-catenin) are putative GSK-3 substrates for phosphory-
lation-dependent inactivation4; therefore, GSK-3 could in-
terfere with tumor development.5 However, although phar-
macologic inhibition of GSK-3 would be expected to
promote cancer, no direct in vivo evidence has indicated
that such a phenomenon occurs on administration of GSK-3
antagonists. In fact, the risk of cancer development among
psychiatric patients treated with lithium salts, long known
as an inhibitor of GSK-3,6 is significantly lower than that
in the general population, suggesting that inhibition of
GSK-3 may have a generally protective effect toward
carcinogenesis.7 Accordingly, recent studies show that
GSK-3 inhibitors lead to significant reduction in cell
growth and proliferation of prostate,8 pancreatic,9 colo-
rectal,10 ovarian,11 medullary thyroid,12 and pheochro-
mocytoma13 cancer cell lines and that GSK-3 activity is
essential for maintenance of a subset of leukemias.14
The first role identified for GSK-3 almost 30 years ago
recognized it as a crucial factor in glucose metabolism,
being the kinase that phosphorylates and inactivates gly-
cogen synthase, the first enzyme in glycogen biosynthe-
sis.15 It is well-known that even in the presence of oxy-
gen, tumors consistently rely on glycolysis to generate a
substantial fraction of total cellular ATP production. Fur-
thermore, tumor cells maintain ATP production by in-
Supported by grants from FIRB-ItalBioNet to L.A.
P.d.C. and G.M. contributed equally to this work.
Accepted for publication December 14, 2010.
Current address of P.d.C., Fondazione Istituto Nazionale Genetica
Molecolare (INGM), Milan, Italy.
Address reprint requests to Paola de Candia, Ph.D., INGM, Via F.
Sforza, 32; 20122, Milan, Italy. E-mail: decandiapaola@ingm.it.
The American Journal of Pathology, Vol. 178, No. 4, April 2011
Copyright © 2011 American Society for Investigative Pathology.
Published by Elsevier Inc. All rights reserved.
DOI: 10.1016/j.ajpath.2010.12.047
1814
creasing glucose influx to fuel the energy requirements of
unrestricted proliferation.16 The role of GSK-3 in this
phenotype is still unclear. Nonetheless, it is conceivable,
although still not completely demonstrated, that GSK-3
could be involved in glucose metabolism of tumor cells
through its effect on glycogen metabolism.
To explore whether altered carbon metabolism of
transformed cells involves GSK-3 dysregulation, we
used murine NIH3T3 cells, a largely studied immortalized
cell line established as a model parental cell line for the
study of cell transformation.17 Similar to most cancer
cells, NIH3T3 cells transformed by an activated form of
the K-ras oncogene exhibit a higher rate of glucose con-
sumption associated with mitochondrial dysfunction.18
So, whereas normal NIH3T3 cells cope with glucose
shortage by relying on oxidative metabolism and decel-
erating cell proliferation, K-ras–transformed cells are re-
markably sensitive to glucose deprivation, losing their
growth advantage and high survival rate.19
Analysis of GSK-3 regulation in K-ras–transformed
fibroblasts and their parental counterparts in conditions
of high versus low glucose availability showed posttrans-
lational inhibition of GSK-3 in the latter condition. This
pattern was uncoupled from regulation of glycogen syn-
thase and -catenin. After this observation, we exposed
normal and transformed cells to glucose deprivation and
GSK-3 chemical inhibition and found that nutrient limi-
tation sensitizes transformed cells, but not parental
NIH3T3, to growth impairment by two different GSK-3
inhibitors. Glucose limitation also rendered more effective
the growth inhibition properties of lithium chloride (LiCl) in
the human neoplastic MDA-MB-231 cells.
Materials and Methods
Cell Culture and Synchronization
Normal murine fibroblasts (obtained from the American
Type Culture Collection, Manassas, VA) and a K-ras–trans-
formed derived cell line (226.4.1),20 A549 lung carcinoma,
HeLa cells, and MDA-MB-231 breast cancer cells were
grown in Dulbecco’s modified Eagle’s medium (Invitrogen,
Carlsbad, CA) containing 10% newborn calf serum (or 10%
fetal bovine serum for human cell lines), 2 mmol/L glu-
tamine, 100 U/mL of penicillin, and 100 mg/mL of strepto-
mycin (normal growth medium) at 37°C in a humidified
atmosphere of 5% CO2. To verify the cell response to glu-
cose depletion, the cells were grown in medium without
glucose and sodium pyruvate (Invitrogen) supplemented
with the appropriate concentration of glucose (25 and 1
mmol/L). For cell growth assays, cells were plated in six-well
plates (NIH3T3 and K-ras–transformed cells at 28,800 cells
per well, A549 at 133,000 cells per well, HeLa at 77,000
cells per well, and MDA-MB-231 at 106,000 cells per well)
and were allowed to attach overnight. The medium was
changed with different concentrations of glucose in the
presence of either carrier (or NaCl) or GSK-3 inhibitors
(three wells were used for each condition). Cells were col-
lected using trypsin-EDTA (Invitrogen) at different time
points and were counted using a Bürker counting chamber.
Cell death was determined by trypan blue (Sigma-Aldrich,
St. Louis, MO) dye exclusion assay. For synchronization in
G2-M phase, cells were incubated for 16 hours with no-
codazole, 100 ng/mL; then, synchronized cells were recov-
ered by gentle shaking, released by the drug-induced
block in fresh medium, and harvested after 4, 6, and 8
hours. For protein kinase B (PKB) inhibition, K-ras–trans-
formed cells were plated in six-well plates at 28,800 cells
per well, and the medium was changed as described. After
72 hours of growth, either wortmannin, 10 mol/L, or di-
methyl sulfoxide alone was added to the medium for 30
minutes, and then cells were harvested for protein evalua-
tion. For AMP-activated protein kinase (AMPK) activa-
tion, cell growth assay was performed, as described
previously herein, in the presence of either carrier or
500 mol/L aminoimidazole carboxamide ribonucle-
otide (Sigma-Aldrich). For K-ras overexpression, 1  106
HeLa cells were transfected with 10 g of a porcine cyto-
megalovirus–transforming–K-ras expression vector as pre-
viously reported21 or with 10 g of a porcine cytomegalo-
virus empty vector using FuGENE (Roche Molecular
Biochemicals, Mannheim, Germany) following the manufac-
turer’s instructions. Twelve hours after transfection, cells
were plated in six-well plates (77,000 cells per well) and
were grown as described previously herein.
RNA Preparation and Real-Time PCR
Total RNA was extracted from NIH3T3 and K-ras–trans-
formed cells using the SV Total RNA Isolation Kit (Pro-
mega, Madison, WI). First-strand cDNA was synthesized
using a High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, Foster City, CA). The first-strand
cDNA was then used as a template for quantitative RT-
PCR with the TaqMan Gene Expression Master Mix and
the specific TaqMan Gene Expression Assays for the
GSK3-, c-src, and -actin genes (Applied Biosystems).
The cycling conditions were as follows: initial denaturation
at 94°C for 2 minutes, followed by 40 cycles of denaturation
at 94°C for 15 seconds and annealing/extension at 60°C for
1 minute. -actin was used as normalizing internal control
for gene expression analyses. Differences in gene expres-
sion were evaluated using a t-test.
Gel Electrophoresis and Immunoblotting
Cells were lysed in radioimmunoprecipitation assay buffer
plus phosphatase and protease inhibitors. After incubation
for 15 minutes on ice, the extracts were centrifuged at
13,200 rpm for 10 minutes. The protein concentration of
supernatant was measured using the Bradford procedure
(Bio-Rad Laboratories, Richmond, CA), using bovine serum
albumin as a standard. Total and fractionated cellular ex-
tracts were subjected to electrophoresis in SDS–polyacryl-
amide gel and were transferred to a nitrocellulose mem-
brane (Amersham, Otelfingen, Switzerland). Membranes
were preincubated in Tris-buffered saline [20 mmol/L Tris-
HCl (pH 7.5), 150 mmol/L NaCl]/5% defatted milk powder
for 1 hour at room temperature and then were incubated in
Tris-buffered saline/–0.01% Tween 20/5% defatted milk
powder containing the appropriate antibodies overnight at
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4°C. The antibodies used were against GSK-3, phospho–
GSK-3 (Ser9), phospho–GSK-3 (Tyr216), glycogen syn-
thase, phospho-glycogen synthase (Ser641), phospho-AKT
substrate, phospho-AMPK (Thr172), and AMPK (Cell Sig-
naling Technology, Beverly, MA); -catenin (BD Transduc-
tion Laboratories, Heidelberg, Germany); N-terminal anti–-
catenin S/T-nonphosphorylated and pan ras (Upstate
Biotechnology, Lake Placid, NY); and vinculin and actin
(Sigma-Aldrich). After three washings (5 minutes each) in
Tris-buffered saline/0.05% Tween 20, the membranes
were incubated with a peroxidase-coupled secondary an-
tibody (Amersham) for 30 minutes at room temperature.
After incubation, the membranes were washed three times
in Tris-buffered saline/0.05% Tween 20. The reaction was
visualized using ECL (Amersham), followed by exposure to
an X-ray film. Images were scanned at a minimum resolu-
tion of 300 dpi. Protein levels were quantified by densitom-
etry of JPEG images using the NIH image-based software
ImageJ.
BrdU Incorporation Assay
For the 5-bromo-2=-deoxyuridine (BrdU) incorporation as-
say, K-ras–transformed cells were grown in duplicate on
polylysine-precoated glass coverslips in six-well plates and
were treated as described previously herein. The cells were
then incubated with 10 mol/L 5-bromo-2=-deoxyuridine
(Roche Molecular Biochemicals) for 5 hours. Cells on cov-
erslips were fixed with paraformaldehyde (4% in PBS, pH
7.4), permeabilized with 0.5% Triton X-100 (Roche Diagnos-
tics GmbH, Mannheim, Germany), and incubated in 0.5-N
HCl for 30 minutes. Coverslips were washed three times
with PBS in a 10-minute period and were incubated with a
primary mouse anti-BrdU antibody (5-Bromo-2=-deoxyuri-
dine Labeling and Detection Kit; Roche Molecular Biochem-
icals) following the instructions of the supplier. Then, the
cells were stained with Alexa Fluor 546–conjugated sec-
ondary antibody (Molecular Probe, Invitrogen), with nuclear
counterstaining with DAPI (Sigma-Aldrich), 1:1000. The
coverslips were mounted in Mowiol (Calbiochem, San Di-
ego, CA) onto a glass microscope slide, and fluorescence
was examined using an Axiophot microscope (Zeiss Jena
GmbH, Jena, Germany). The number of total and BrdU-
positive cells in each condition were counted in 10 nonover-
lapping fields per coverslip, and the quantification of BrdU-
positive cells per total number of DAPI–positive nuclei was
determined as a mean  SD percentage.
Flow Cytometric Analysis
The distribution of cells at specific cell cycle phases was
evaluated by flow cytometry as previously described.22
Figure 1. Parental and K-ras–transformed fibroblasts were plated at 3000 cells/cm2 density. After 16 hours of growth, the medium was changed with a glucose
concentration maintained at 25 mmol/L (A) and with a glucose concentration of either 25 or 1 mmol/L (B). Cells were harvested after 24 hours (A) or after 24,
48, and 72 hours (B). Total RNA was prepared and was subjected to real-time PCR with oligonucleotides specific to GSK-3 (A) or to GSK-3 and c-src genes
(B), as indicated. Each sample was normalized by -actin internal control. Results are the mean of biological triplicate determinations and were plotted considering
the value obtained for parental samples mean (A) or time 0 (B) as equal to 1. For protein expression analysis, normal and transformed cells were plated and grown
as described previously herein in 25 mmol/L glucose and were collected at 24 hours. Proteins (50 g) from total cellular extracts of biological triplicates were
subjected to SDS–polyacrylamide gel electrophoresis, followed by Western blotting with an anti–GSK-3 antibody. Relative quantitative values of protein levels
after Western blot film acquisition were obtained by densitometric analysis using the ImageJ program and then were plotted considering the densitometric value
obtained for the parental samples mean as equal to 1. Error bars represent SD. *P  0.05 for the t-test.
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Briefly, cells were trypsinized, washed with PBS, and
fixed in 75% ethanol at 4°C. Subsequently, samples were
stained with propidium iodide (Sigma-Aldrich) and were
analyzed using a fluorescence-activated cell sorter (FAC-
Scan; BD Biosciences, Franklin Lakes, NJ), using Cell
Quest software (BD Biosciences). Data analysis was per-
formed using WinMDI software.
Results
GSK-3 mRNA Is Induced by Glucose
Limitation
Parental and K-ras–transformed fibroblasts were plated
at 3000 cells/cm2 density. After 16 hours of growth, the
medium was changed with a glucose concentration
maintained at 25 mmol/L. Twenty-four hours after medium
change, in the condition of exponential growth, we har-
vested parental and transformed cells and prepared total
RNA to evaluate the mRNA levels of GSK-3 using real-
time PCR. Transformed cells showed a lower mRNA level
for GSK-3, and the protein level was also sensibly lower
in transformed versus parental cells as assessed by
Western blotting (Figure 1A).
Normal and transformed cells were then plated as de-
scribed previously herein, and after 16 hours, the medium
was changed (cells were also harvested at this time, re-
ferred to as time 0). Media were supplemented with either
high (25 mmol/L) or low (1 mmol/L) glucose concentration.
Cells were then harvested after 24, 48, and 72 hours of
growth. All the experiments reported in this and the follow-
ing paragraphs refer to the previously mentioned experi-
mental setup, already used for several studies.18,19
To evaluate the effect of glucose shortage on GSK-3
regulation, we prepared RNA from normal and K-ras–
transformed NIH3T3 cells grown in either high or low
glucose availability. GSK-3 mRNA levels were mea-
sured using real-time PCR. In normal and transformed
cells, the level of mRNA for GSK-3 was constant until 48
hours of growth and increased at 72 hours in low glucose,
more substantially in transformed cells (Figure 1B, top).
This time-dependent expression pattern was specific for
GSK-3 mRNA and was not a general response to glu-
cose limitation because expression of an unrelated gene,
c-src, remained constant over the timeframe of the ex-
periment (Figure 1B, bottom).
Preferential GSK-3 Inhibition in Transformed
Cells Grown in Low Glucose
The GSK-3 protein level remained fairly stable over time
in normal and transformed cells, with no increase at late
time points in low glucose (Figure 2A), suggesting a
compensatory mechanism for the observed transcrip-
tional activation. In K-ras–transformed cells, the level of
GSK-3 inhibitory phosphorylation at Ser9 was consis-
tently higher in low compared with high glucose, with the
largest difference at 72 hours. On the other hand, acti-
vating Tyr216 phosphorylation was slightly decreased in
low versus high glucose at the same time point (Figure
2A). Through quantification of Western blotting by Im-
ageJ, we showed an increase in the ratio between Ser9
phosphorylated and total protein over time specifically in
low glucose and a 12-fold difference of this ratio in low
versus high glucose at 72 hours (Figure 2B, top). In
normal cells, on the other hand, Ser9 phosphorylation did
Figure 2. A: K-ras–transformed and parental fi-
broblasts were plated at 3000 cells/cm2 density.
After 16 hours of growth, the medium was
changed with a glucose concentration of either
25 or 1 mmol/L, and cells were harvested at
specific time points, as indicated. For protein
expression analysis, proteins (50 g) from total
cellular extracts of transformed or normal cells
were subjected to SDS–polyacrylamide gel electro-
phoresis, followed by Western blotting with the
indicated antibodies. One of at least three inde-
pendent experiments is shown. Vinculin was used
as a control of equal gel loading. B: Transformed
(top) and parental (bottom) cells were plated,
grown as described previously herein, and har-
vested 24 and 72 hours after medium change.
Proteins from three independent cellular extracts
were subjected to SDS–polyacrylamide gel elec-
trophoresis, followed by Western blotting for the
indicated proteins, and then their quantitative
values were plotted considering the densitomet-
ric value obtained for the sample in 25 mmol/L
glucose at 24 hours as equal to 1. Results are the
mean of triplicate determinations. Error bars rep-
resent SD. *P  0.05 for the t-test.
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not increase significantly or even decreased over time
also in low glucose, and the difference between high and
low glucose at 72 hours was less pronounced than in
transformed cells (Figure 2B, bottom).
Given that GSK-3 is known to inhibit cell proliferation
and glycogen accumulation mainly through phosphory-
lation of -catenin and glycogen synthase, respectively,
we analyzed the regulation of these targets in cells grown
in either high or low glucose. Activation of -catenin was
evaluated by using an antibody specific for the active
form of the protein, dephosphorylated on Ser37 or Thr41.
As shown in Figure 2A, neither the phosphorylation pat-
tern nor total protein accumulation seemed to be affected
by glucose deprivation in normal and transformed cells.
Quantification analysis performed on triplicates at 24 and
72 hours confirmed that the ratio between the activated
and total forms of the protein was not modulated in the
two cell lines (Figure 2B). We also evaluated -catenin
nuclear localization in transformed cells: at 24 and 72
hours, the total and active forms of -catenin were mostly
in the nuclear/insoluble fraction, and this pattern was
likewise not affected by glucose availability (data not
shown). In contrast to the observed GSK-3 phosphory-
lation pattern, glycogen synthase seemed to be phos-
phorylated at a higher level after 72 hours of growth in low
compared with high glucose in normal and transformed
cells (Figure 2A). The quantitative analysis of the ratio
between the phosphorylated and total forms of the pro-
tein confirmed that glycogen synthase phosphorylation
was increased in low glucose– versus high glucose–
grown cells, with the difference being larger in normal
cells than in transformed cells (Figure 2B).
Glucose Limitation Sensitizes Transformed Cells
to Growth Impairment by GSK-3 Antagonists
The observation that GSK-3 posttranslational inhibition
increased in conditions of nutrient limitation prompted us
to evaluate the effect of GSK-3 inhibition on proliferation
of normal and transformed NIH3T3 cells. To this end, we
treated both cell lines grown in either high or low initial
glucose with the GSK-3 inhibitor LiCl, using NaCl as an
isotonic control. During the experiment, K-ras–trans-
formed cells grew significantly less in media supple-
mented with low as opposed to high initial glucose con-
centrations (Figure 3A, left), as previously reported.19
Cell growth was significantly further inhibited by the ad-
dition of LiCl (Figure 3A, left; P  0.05).
Sb-216763, a cell-permeable maleimide compound that se-
lectively inhibits GSK-3,23 failed to inhibit proliferation of K-ras–
transformed cells grown in media supplemented with a high
initial glucose concentration (Figure 3A, right) when used at a
concentration of 25 mol/L. On the other hand, this concen-
tration was sufficient to effectively inhibit growth of transformed
cells grown with low glucose availability (Figure 3A, right; P 
0.05). A higher concentration (50 mol/L) of the drug was
necessary to observe an effect similar to that observed with
lithium (data not shown). These data thus suggest that
K-ras–transformed NIH3T3 fibroblasts are exquisitely
sensitive to GSK-3 inhibition when grown under con-
ditions of glucose limitation. Normal NIH3T3 cells grew
similarly in media supplemented with different glucose
concentrations (Figure 3B), and LiCl had little, if any,
inhibitory effect (Figure 3B, left). Similar to LiCl, Sb-
216763 did not affect the growth of parental cells (Fig-
ure 3B, right).
K-ras–transformed cells could not sustain their growth
through the citric acid cycle because cells did not restore
a normal growth rate when medium was supplemented
with sodium pyruvate (Figure 4A). This result is in keeping
with previous studies showing that K-ras–transformed
cells have defective mitochondria19 and, more specifi-
cally, that the reduction in respiration observed is due to
a decrease in complex I activity.24
In Transformed Cells, Glucose Limitation
Activates AMPK Only When GSK-3 Is
Pharmacologically Inhibited
To ascertain whether the PI3K/PKB pathway was responsi-
ble of the increased Ser9 phosphorylation of GSK-3 in the
condition of glucose shortage, transformed cells were
grown in either high or low glucose, and 72 hours after
medium change, cells were treated with wortmannin, a spe-
cific inhibitor of PI3K. The subsequent inhibited activity of
PKB on wortmannin exposure was evaluated by Western
blotting using an antibody that recognizes the phospho-
(Ser/Thr) PKB substrate motif (RXXS/T). This control showed
similar suppression of the phosphorylation level for different
PKB substrates (Figure 4B). On the other hand, whereas
wortmannin treatment dramatically inhibited GSK-3 phos-
Figure 3. K-ras–transformed (A) and parental (B) fibroblasts were plated at
3000 cells/cm2 density in six-well plates. After 16 hours of growth, the
medium was changed with those shown. Cells were collected by trypsiniza-
tion at the indicated times and were counted using a Bürker counting
chamber. The fold increase in cell number was plotted considering the cell
number at time 0 as equal to 1. The experiment reported is representative of
three different ones. Results are the mean of triplicate determinations in a
single experiment. Error bars represent SD. DMSO, dimethyl sulfoxide. *P 
0.05 for the t-test.
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phorylation in high glucose, it only marginally decreased it
in low glucose (Figure 4B), suggesting that in the condition
of nutrient depletion, kinases other than PKB are responsi-
ble for the observed Ser9 phosphorylation.
Normal cells are known to have a lower rate of nutrient
consumption than transformed cells and not to consume the
glucose completely during the exponential phase of growth
in conditions of glucose shortage.19 Consequently, we ob-
served that normal cells did not activate AMPK after 72
hours of growth in 1 mmol/L glucose, as assessed by the
lack of activating phosphorylation on AMPK Thr172 (Figure
4D). On the other hand, transformed cells do consume
glucose very rapidly.19 We confirmed this by observing
complete consumption of glucose already at 48 hours of
growth in 1 mmol/L glucose (data not shown). Unexpect-
edly, though, glucose depletion was unable to activate
AMPK, not even at 72 hours, and only when glucose short-
age was combined with GSK-3 inhibition, phospho-AMPK
was clearly detected by Western blotting (Figure 4D). In
transformed cells, AMPK activation was a strong signal of
cell growth inhibition; in fact, treatment with a specific
AMPK-activating drug, aminoimidazole carboxamide ribo-
nucleotide, caused complete suppression of proliferation,
independent of glucose availability (Figure 4C).
Glucose Limitation Dramatically Enhances the
Inhibition of Cell Proliferation Due to GSK-3
Inactivating Drugs
Reduced cell growth of K-ras–transformed cells in low
glucose has been shown to be partly due to increased
apoptosis.19 To ascertain whether the reduced growth in
the presence of GSK-3 inhibitors was due to an effect on
cell death and/or cell proliferation, the overall cell viability
of K-ras–transformed cells and their ability to enter S
phase were monitored. To evaluate the level of cell death,
we harvested adherent and floating cells and ran a trypan
Figure 4. A: K-ras–transformed cells were plated as described previously herein, and at the time of medium change, to the above media were added either
sodium pyruvate or its vehicle, as indicated. Cells were collected by trypsinization at the indicated times and were counted using a Bürker counting chamber. The
fold increase in cell number was plotted considering cell number at time 0 as equal to 1. Results are the mean of triplicate determinations in a single experiment.
Error bars represent SD. B: K-ras–transformed cells were plated at 3000 cells/cm2 density. After 16 hours of growth, the medium was changed with a glucose
concentration of either 25 or 1 mmol/L. At 72 hours of growth, cells were treated with wortmannin, 10 mol/L [or with dimethyl sulfoxide (DMSO) alone], for
30 minutes and then were harvested. For protein expression analysis, proteins (50 g) from total cellular extracts were subjected to SDS–polyacrylamide gel
electrophoresis, followed by Western blotting with the indicated antibodies. C: K-ras–transformed cells were plated as described previously herein, and at the time
of medium change, to the above media were added either aminoimidazole carboxamide ribonucleotide (AICAR) or PBS alone, as indicated. Cells were collected
by trypsinization at the indicated times and were counted using a Bürker counting chamber. The fold increase in cell number was plotted considering cell number at
time 0 as equal to 1. Results are the mean of triplicate determinations in a single experiment. D: K-ras–transformed and parental fibroblasts were grown in either 25 or
1 mmol/L glucose plus 10 mmol/L NaCl or LiCl, as indicated. Cells were harvested after 72 hours of growth, and for protein expression analysis, proteins (50 g) from
total cellular extracts were subjected to SDS–polyacrylamide gel electrophoresis, followed by Western blotting with the indicated antibodies. Error bars represent SD.
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blue exclusion assay. The percentage of trypan blue
positive over total cell number was comparable for differ-
ent treatments at 24 and 48 hours (Figure 5A, top). At 72
hours, however, the amount of dead cells increased spe-
cifically when cells were glucose depleted, thereby con-
firming previous findings.19 Even at this time point, no
relevant differences between cells treated with lithium
and the control were observed, and the same observa-
tion was made with Sb-216763 (data not shown).
Therefore, to analyze whether cell proliferation was,
indeed, responsible for the apparent inhibition of cell
growth, the percentage of cells in S phase was measured
by analyzing BrdU incorporation in DNA. We incubated
cells for 5 hours with BrdU before each time point (ie, at
24 and 48 hours). At 24 hours, the level of BrdU incorpo-
ration was comparable in high glucose, high glucose
plus lithium, or low glucose, whereas it was already sig-
nificantly lower in cells growing in low glucose plus lith-
ium (Figure 5A, center). At 48 hours, the inhibition of
GSK-3 caused a moderate decrease in the percent-
age of BrdU-positive cells, but the effect was dramat-
ically more pronounced when lithium was used in combi-
nation with low glucose (Figure 5A, center; P  0.05).
Similar patterns were obtained with Sb-216763 (data not
shown). Taken together, these results indicate that GSK-3
inhibition brought about by either LiCl or Sb-216763 in glu-
cose-depleted transformed cells is due to reduced prolifer-
ation, with no substantial effect on cell death.
LiCl Delays the Cell Cycle of Transformed Cells
by Impairing Exit from M Phase
To further analyze the role of GSK-3 in cell proliferation,
we evaluated cell cycle distribution by propidium iodide
Figure 5. A, top: K-ras–transformed fibroblasts were plated at 3000 cells/cm2 density and were grown on polylysine-precoated glass coverslips. After 16 hours
of growth, the medium was changed with those shown. Adherent and floating cells were collected at the indicated time points, and dead cells were evaluated
using a trypan blue exclusion assay. Percentage of trypan blue–positive over total cells was plotted as a mean value of biological triplicates. A, center: Transformed
cells were plated at 3000 cells/cm2 density in six-well plates. They were treated as described previously herein and then were pulsed 5 hours with BrdU before harvesting
at the indicated time points. The cells were analyzed by fluorescence microscopy using an anti-BrdU–specific antibody. The numbers of total and BrdU-positive cells in
each condition were counted in 10 nonoverlapping fields per coverslip, and the quantification of BrdU-positive cells per total numbers of DAPI–positive nuclei was
determined as a mean percentage taking into account two independent experiments. A, bottom: Transformed cells were plated at 3000 cells/cm2 density in 145-mm
plates. They were treated as described previously herein and then were collected at the indicated time points after medium change, stained with propidium iodide, and
analyzed using a fluorescence-activated cell sorter. The ratio G2-M/G1 was plotted considering the ratio of cells growing in high glucose at 24 hours as equal to 1. Error
bars represent SD. *P  0.05 for the t-test. B: Transformed cells were plated as described previously herein and were grown in 25 mmol/L glucose for 48 hours. Cells
were then treated with nocodazole (NOC), 100 ng/mL, for 16 hours; synchronized cells were released and harvested at the indicated time points. They were then stained
with propidium iodide and were analyzed using a fluorescence-activated cell sorter. The experiment reported is representative of three different ones. Results are the
mean of triplicate determinations in a single experiment. Error bars represent SD. *P  0.05 for the t-test.
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incorporation and cytofluorimetric analysis. The ratio of
cells in G2-M over cells in G1 increased significantly in
lithium-treated cells compared with the isotonic control at
all time points and independent of glucose concentra-
tion, suggesting a discrete accumulation of these cells
in G2-M phase of the cell cycle (Figure 5A, bottom). To
study the possible effect of GSK-3 inhibition on exit
from mitosis, cells grown in high glucose were blocked
in M phase by 16 hours of treatment with nocodazole, a
microtubule destabilizer known to induce a mitotic check-
point arrest. To determine the drug-induced accumulation
of cells in mitosis, control- and nocodazole-treated cells
were stained with propidium iodide, showing the efficacy of
the block with greater than 95% of cells with a 4-N DNA
content (Figure 5B). Blocked cells were harvested by gentle
shaking and were released from the block with high glucose
medium in the presence of either LiCl or the isotonic control.
Although 50% of control-treated cells had completed M
phase and entered G1 phase approximately 4 hours after
the release, lithium-treated cells took approximately 8 hours
to reach the same percentage of cells with a 2-N DNA
content, indicating that GSK-3 inhibition causes a dra-
matic delay in exit from mitosis in this setting (Figure 5B).
Human Neoplastic Cell Lines Show Different
Responses to LiCl
To evaluate whether the cooperative effect in growth in-
hibition observed in K-ras–transformed NIH3T3 was spe-
cific to murine fibroblasts, we analyzed the behavior of
two human cell lines, lung carcinoma A549 and breast
cancer MDA-MB-231, both harboring an activated ras
pathway. Their growth was sensitive to glucose concen-
tration (Figure 6, A and B), although to a different extent.
MDA-MB-231 cells had similar GSK-3 protein levels
(data not shown), but they were much more sensitive to
glucose deprivation: in 1 mmol/L glucose, they grew
poorly in the first 24 hours, and a dramatic reduction in
cell number was apparent at 72 hours (Figure 6B). Strik-
ingly, LiCl completely blocked cell growth of glucose-
depleted cells as early as 24 hours after addition, and
severe cell loss started at 48 hours (Figure 6B; P  0.05).
HeLa cells were also sensitive to glucose depletion, al-
though to a lesser extent, whereas the cooperative effect
of glucose shortage and GSK-3 inhibition on cell growth
was almost undetectable (Figure 6C). They did not ac-
quire sensitivity when transfected with an activated trans-
forming K-ras gene,21 suggesting that ras activation is not
the only factor determining the cellular sensitivity of trans-
formed cells to glucose deprivation plus GSK-3 inhibi-
tion (Figure 6D). The experiment could not go beyond 42
hours of growth, when the exogenous K-ras expression
had disappeared (Figure 6D, inset).
Discussion
The serine/threonine kinase GSK-3 has been carefully
described as being inhibited by insulin signaling in con-
ditions of high nutrient availability; consequently, it is
expected to be active under conditions of low glucose.
The work presented herein goes against this dogma,
showing that murine fibroblasts, in fact, repress GSK-3
action through Ser9 phosphorylation in conditions of glu-
cose shortage. This phenomenon is much more impor-
tant in K-ras–transformed cells than in their normal coun-
terparts. By using a PI3K inhibitor, we analyzed the role of
Figure 6. The A549 (A), MDA-MB-231 (B), and HeLa (C)
human neoplastic cell lines were plated at 133,000, 106,000,
and 77,000 cells per well, respectively, in six-well plates. After
16 hours of growth, the medium was changed with those
shown. Cells were collected by trypsinization at the indicated
time points and were counted using a Bürker counting cham-
ber. The fold increase in cell number was plotted considering
cell number at time 0 as equal to 1. The experiment was
performed in triplicate. Error bars represent SD. *P  0.05 for
the t-test. D: HeLa cells, 1  106, were transfected with 10 g
of a porcine cytomegalovirus–transforming K-ras expression
vector or with the same amount of a porcine cytomegalovirus
empty vector. Twelve hours after transfection, cells were
plated in six-well plates (77,000 cells per well) and were grown
as described previously herein. Error bars represent SD.
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the pathway in these cells and found that PKB is only
marginally responsible for the signal at Ser9 in low glu-
cose, suggesting that other pathways are, indeed, in-
volved in this regulation.
Starting from this unexpected observation, the major
result presented in this work is the first demonstration that
glucose limitation sensitizes K-ras–transformed fibro-
blasts to pharmacologic growth inhibition by two GSK-3
antagonists, LiCl and Sb-216763. The two molecules in-
hibit GSK-3 through different mechanisms: lithium di-
rectly inhibits GSK-3 by competing with magnesium but
not with substrate or ATP,25 whereas Sb-216763 inhibits
GSK-3 in an ATP-competitive manner.23 Results ob-
tained with Sb-216763 are particularly striking because
when given at 25 mol/L, this inhibitor is completely in-
effective on transformed cells grown in the presence of
high glucose, whereas it significantly impairs growth
when given to cells in low-glucose media.
During the experiments reported herein, GSK-3–neg-
ative regulation by glucose availability was uncoupled
from -catenin accumulation, phosphorylation, and intra-
cellular localization. This behavior is consistent with stud-
ies showing that the correlation between GSK-3 and
-catenin could be looser than initially thought, with no
-catenin accumulation being found in tissues of GSK-3
knockout mice.26 Furthermore, an extensive study of co-
lon cancer cell lines and tumor samples revealed that the
expression level or activity of GSK-3 does not correlate
with -catenin activation.10 We showed that only when
treated with LiCl could transformed cells activate AMPK in
low glucose: this result is highly significant because it shows
that these cells cannot sense nutrient deprivation through
the AMPK pathway unless GSK-3 is completely blocked,
and it is also in keeping with the cross talk between AMPK
and GSK-3 reported in rat isolated muscle.27
Different effects of GSK-3 antagonists on the cell
cycle have been reported. These effects include induc-
tion of G1 arrest,14 impaired spindle dynamics, delay in
chromosome alignment, and mitotic entry-exit and cell
cycle arrest at G2-M.28,29 In keeping with the latter stud-
ies, propidium iodide–stained K-ras–transformed cells
showed a significant increase in the percentage of G2-M
phase subpopulations in cells treated with LiCl due to a
specific delay in exit from mitosis. Interestingly, AMPK
has been implicated in cell division in distant cellular
contexts,30 so we are interested in analyzing the role that
the AMPK pathway exerts in mitotic defects shown by
LiCl-treated transformed cells.
Moreover, it has been described that regulation of
reactive oxygen species (ROS) concentrations has a def-
inite role on the rate of cell cycle progression31 and that
ROS production could be crucial for mitotic events in
tumor cells, with reduced levels of ROS delaying spindle
assembly and exit from mitosis.32 In the present trans-
formed cells, lithium treatment caused a specific decrease
in ROS levels, evaluated by 2,7-dichlorofluorescein diace-
tate assay, and this effect was augmented in low glucose
(data not shown), suggesting that GSK-3 pharmacologic
inhibition could delay exit from mitosis, at least in part, by
impairing the production of intracellular ROS.
We observed a dramatic effect of low glucose on LiCl
sensitivity not only of murine K-ras–transformed fibro-
blasts but also of MDA-MB-231 cells. These cells, de-
rived from human breast carcinoma, grew very poorly in
low glucose and could not grow at all when also treated
with lithium. MDA-MB-231 cells have an activated ras
gene, similar to our NIH3T3 fibroblasts, and a further
mutation in the rafB gene, encoding a kinase in the same
pathway (http://www.sanger.ac.uk/perl/genetics/CGP/
cosmic?actionsample&id905960, last accessed Feb-
ruary 2011). Growth of A549 cells, also harboring a ras
activating mutation,33 was not dramatically inhibited in
conditions of low glucose and LiCl, and HeLa cells trans-
fected with an activated ras allele did not acquire any
further sensitivity to the treatment, suggesting that ras
pathway deregulation is not the only factor determining
cancer cell sensitivity to the cooperation effect between
nutrient limitation and GSK-3 pharmacologic inhibition.
The interrelationship between drug treatment and nu-
tritional stress is not limited to GSK-3 inhibition. Starva-
tion-dependent differential stress resistance has been
reported to protect normal cells, but not transformed
cells, against chemotherapy,34 suggesting that modula-
tion of the nutritional status of cancer cells may be a
valuable tool in cancer therapy of possibly wide applica-
bility. The ability of cells to respond to nutritional stress
seems, thus, to be an important property to score in
genotype-phenotype correlation studies that, as has
been pointed out recently,35 must be placed in context to
give prognostic and therapeutic value to the large num-
ber of personal genome sequences that are expected to
be obtained in the next few years.
Acknowledgments
We thank Tommaso Russo for precious advice, Addolo-
rata Maria Luce Coluccia for sharing reagents, and Ro-
berta Visconti for stimulating discussions.
References
1. Kockeritz L, Doble B, Patel S, Woodgett JR: Glycogen synthase
kinase-3: an overview of an over-achieving protein kinase. Curr Drug
Targets 2006, 11:1377–1388
2. Rayasam GV, Tulasi VK, Sodhi R, Davis JA, Ray A: Glycogen syn-
thase kinase 3: more than a namesake. Br J Pharmacol 2009, 156:
885–898
3. Martinez A: Preclinical efficacy on GSK-3 inhibitors: towards a future
generation of powerful drugs. Med Res Rev 2008, 28:773–796
4. Manoukian AS, Woodgett JR: Role of glycogen synthase kinase-3 in
cancer: regulation by Wnts and other signaling pathways. Adv Can-
cer Res 2002, 84:203–229
5. Polakis P: The oncogenic activation of beta-catenin. Curr Opin Genet
Dev 1999, 9:15–21
6. Stambolic V, Ruel L, Woodgett JR: Lithium inhibits glycogen synthase
kinase-3 activity and mimics wingless signalling in intact cells. Curr
Biol 1996, 6:1664–1668
7. Cohen Y, Chetrit A, Cohen Y, Sirota P, Modan B: Cancer morbidity in
psychiatric patients: influence of lithium carbonate treatment. Med
Oncol 1998, 15:32–36
8. Mazor M, Kawano Y, Zhu H, Waxman J, Kypta RM: Inhibition of
glycogen synthase kinase-3 represses androgen receptor activity
and prostate cancer cell growth. Oncogene 2004, 23:7882–7892
1822 de Candia et al
AJP April 2011, Vol. 178, No. 4
9. Ougolkov AV, Fernandez-Zapico ME, Savoy DN, Urrutia RA,
Billadeau DD: Glycogen synthase kinase-3 participates in nuclear
factor B-mediated gene transcription and cell survival in pancreatic
cancer cells. Cancer Res 2005, 65:2076–2081
10. Shakoori A, Ougolkov A, Yu ZW, Zhang B, Modarressi MH, Billadeau
DD, Mai M, Takahashi Y, Minamoto, T. Deregulated GSK3 activity in
colorectal cancer: its association with tumor cell survival and prolif-
eration. Biochem Biophys Res Commun 2005, 334:1365–1373
11. Cao Q, Lu X, Feng YJ: Glycogen synthase kinase-3 positively reg-
ulates the proliferation of human ovarian cancer cells. Cell Res 2006,
16:671–677
12. Kunnimalaiyaan M, Vaccaro AM, Ndiaye MA, Chen H: Inactivation of
glycogen synthase kinase-3, a downstream target of the raf-1 path-
way, is associated with growth suppression in medullary thyroid
cancer cells. Mol Cancer Ther 2007, 6:1151–1158
13. Kappes A, Vaccaro A, Kunnimalaiyaan M, Chen H: Lithium ions: a
novel treatment for pheochromocytomas and paragangliomas. Sur-
gery 2007, 141:161–165
14. Wang Z, Smith KS, Murphy M, Piloto O, Somervaille TC, Cleary ML:
Glycogen synthase kinase 3 in MLL leukaemia maintenance and
targeted therapy. Nature 2008, 455:1205–1209
15. Rylatt DB, Aitken A, Bilham T, Condon GD, Embi N, Cohen P: Glyco-
gen synthase from rabbit skeletal muscle: amino acid sequence at
the sites phosphorylated by glycogen synthase kinase-3, and exten-
sion of the N-terminal sequence containing the site phosphorylated
by phosphorylase kinase. Eur J Biochem 1980, 107:529–537
16. Gatenby RA, Gawlinski ET: The glycolytic phenotype in carcinogen-
esis and tumor invasion: insights through mathematical models. Can-
cer Res 2003, 63(14):3847–3854
17. Kahn S, Yamamoto F, Almoguera C, Winter E, Forrester K, Jordano J,
Perucho M: The c-K-ras gene and human cancer (review). Anticancer
Res 1987, 7:639–652
18. Chiaradonna F, Gaglio D, Vanoni M, Alberghina L: Expression of
transforming K-Ras oncogene affects mitochondrial function and
morphology in mouse fibroblasts. Biochem Biophys Acta 2006, 1757:
1338–1356
19. Chiaradonna F, Sacco E, Manzoni R, Giorgio M, Vanoni M, Al-
berghina L: Ras-dependent carbon metabolism and transformation in
mouse fibroblasts. Oncogene 2006, 25:5391–5404
20. Pulciani S, Santos E, Long LK, Sorrentino V, Barbacid M: Ras gene
amplification and malignant transformation. Mol Cell Biol 1985,
5:2836–2841
21. Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B: Sup-
pression of human colorectal carcinoma cell growth by wild-type p53.
Science 1990, 249:912–915
22. Gaglio D, Soldati C, Vanoni M, Alberghina L, Chiaradonna F: Glu-
tamine deprivation induces abortive s-phase rescued by deoxyribo-
nucleotides in k-ras transformed fibroblasts. PLoS One 2009, 4:e4715
23. Coghlan MP, Culbert AA, Cross DA, Corcoran SL, Yates JW, Pearce
NJ, Rausch OL, Murphy GJ, Carter PS, Roxbee Cox L, Mills D, Brown
MJ, Haigh D, Ward RW, Smith DG, Murray KJ, Reith AD, Holder JC:
Selective small molecule inhibitors of glycogen synthase kinase-3
modulate glycogen metabolism and gene transcription. Chem Biol
2000, 7:793–803
24. Baracca A, Chiaradonna F, Sgarbi G, Solaini G, Alberghina L, Lenaz
G: Mitochondrial Complex I decrease is responsible for bioenergetic
dysfunction in K-ras transformed cells. Biochim Biophys Acta 2010,
1797:314–323
25. Ryves WJ, Harwood AJ: Lithium inhibits glycogen synthase kinase-3
by competition for magnesium. Biochem Biophys Res Commun 2001,
280:720–725
26. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR: Require-
ment for glycogen synthase kinase-3 in cell survival and NF-B
activation. Nature 2000, 406:86–90
27. Fediuc S, Gaidhu MP, Ceddia RB: Inhibition of insulin-stimulated
glycogen synthesis by 5-aminoimidasole-4-carboxamide-1-beta-d-
ribofuranoside-induced adenosine 5=-monophosphate-activated pro-
tein kinase activation: interactions with Akt, glycogen synthase kinase
3-3alpha/beta, and glycogen synthase in isolated rat soleus muscle.
Endocrinology 2006, 147:5170–5177
28. Wakefield JG, Stephens DJ, Tavaré JM: A role for glycogen synthase
kinase-3 in mitotic spindle dynamics and chromosome alignment.
J Cell Sci 2003, 116(Pt 4):637–646
29. Tighe A, Ray-Sinha A, Staples OD, Taylor SS: GSK-3 inhibitors induce
chromosome instability. BMC Cell Biol. 2007, 8:34
30. Williams T, Brenman JE: LKB1 and AMPK in cell polarity and division.
Trends Cell Biol 2008, 18:193–198
31. Sarsour EH, Kumar MG, Chaudhuri L, Kalen AL, Goswami PC: Redox
control of the cell cycle in health and disease. Antioxid Redox Signal
2009, 11:2985–3011
32. Visconti R, Grieco D: New insights on oxidative stress in cancer. Curr
Opin Drug Discov Devel 2009, 12:240–245
33. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF,
Schinzel AC, Sandy P, Meylan E, Scholl C, Fröhling S, Chan EM, Sos
ML, Michel K, Mermel C, Silver SJ, Weir BA, Reiling JH, Sheng Q,
Gupta PB, Wadlow RC, Le H, Hoersch S, Wittner BS, Ramaswamy S,
Livingston DM, Sabatini DM, Meyerson M, Thomas RK, Lander ES,
Mesirov JP, Root DE, Gilliland DG, Jacks T, Hahn WC: Systematic
RNA interference reveals that oncogenic KRAS-driven cancers re-
quire TBK1. Nature 2009, 462:108–112
34. Raffaghello L, Lee C, Safdie FM, Wei M, Madia F, Bianchi G, Longo
VD: Starvation-dependent differential stress resistance protects nor-
mal but not cancer cells against high-dose chemotherapy. Proc Natl
Acad Sci U S A 2008, 105:8215–8220
35. Snyder M, Weissman S, Gerstein M: Personal phenotypes to go with
personal genomes. Mol Syst Biol 2009, 5:273
Glucose Limitation and GSK-3 Antagonists 1823
AJP April 2011, Vol. 178, No. 4
Critical Review
Fe65 Matters: New Light on an Old Molecule
Giuseppina Minopoli1,2, Anna Gargiulo2, Silvia Parisi1,2, and Tommaso Russo1,2
1Dipartimento di Biochimica e Biotecnologie Mediche, Universita` di Napoli Federico II, Napoli, Italy
2CEINGE Biotecnologie Avanzate, Napoli, Italy
Summary
The discovery that the main constituents of amyloid deposits,
characteristic of Alzheimer neuropathology, derive from the
proteolytic processing of the membrane precursor amyloid pre-
cursor protein (APP) is one of the milestones of the research
history of this disease. Despite years of intense studies, the func-
tions of APP and of its amyloidogenic processing are still under
debate. One focus of these studies was the complex network of
protein–protein interactions centered at the cytosolic domain of
APP, which suggests the involvement of APP in a lively signal-
ing pathway. Fe65 was the first protein to be demonstrated to
interact with the APP cytodomain. Starting from this observa-
tion, a large body of data has been gathered, indicating that
Fe65 is an adaptor protein, which binds numerous proteins, fur-
ther than APP. Among these proteins, the crosstalk with Mena,
mDab, and Abl suggested the involvement of the Fe65–APP
complex in the regulation of cell motility, with a relevant role
in differentiation and development. Other partners, like the his-
tone acetyltransferase Tip60, indicated the possibility that the
nuclear fraction of Fe65 could be involved in gene regulation
and/or DNA repair.  2012 IUBMB
IUBMB Life, 00: 000–000, 2012
Keywords neurodegenerative disorders; transcription; DNA damage;
cytoskeleton; adaptor proteins.
INTRODUCTION
Alzheimer’s disease (AD) is a neurodegenerative disorder
that represents the most common form of dementia. The amy-
loid precursor protein (APP) has been in the limelight of the
research on AD pathogenesis for more than 20 years. Many
research groups focused their activity on this molecule, because
its proteolytic processing by b- and c-secretases gives rise to
the b-amyloid peptides (Ab). The latter are the main constitu-
ents of the senile plaques, which for many years were believed
to be the pathologic trigger of AD. A large body of literature
suggests that soluble oligomers of Ab, in particular those
involving Ab42, interfere with synaptic plasticity and/or with
memory functions (1). Although several reports questioned the
relevance of Ab in AD pathogenesis (2), the involvement of
APP and its processing is undisputed, being supported by solid
genetic data, indicating that the rare forms of familial AD are
caused by mutations of the APP gene or of the presenilin genes,
which encode the catalytic activity of c-secretase (3).
Experimental evidence supports the possibility that APP and/or
c-secretase dysfunction could lead to neurodegeneration (2).
Obviously, the understanding of the functions of APP and of its
processing is crucial to explore loss of function hypotheses in
the pathogenesis of AD.
In 1995, we observed that the NPXY motif present in the
small cytodomain of APP interacts with a PTB/PI domain of a
protein of unknown function, named Fe65 (4, 5). This finding
was followed by several new observations indicating that, fur-
ther than with Fe65, the same region of APP can also interact
with other proteins such as X11, JIP1, mDab, Numb, Shc, and
Grb2 (6). Many of these partners have the characteristics of
adaptor proteins, thus suggesting the existence of complex
molecular machineries that are centered at the APP cytodomain.
These findings opened a new promising scenario to understand
the functions and the regulation of APP and of its processing,
which could contribute to further understand the molecular basis
of AD. Several review articles describe the main results on this
topic. This review will focus only on one aspect of the entire
story that aimed at addressing the function of Fe65.
THE ADAPTOR PROTEIN Fe65
Fe65 belongs to a protein family, evolutionarily conserved
from worms to humans, which in mammals includes two more
paralogs, Fe65L1 (7) and Fe65L2 (8), which share striking
amino acid and domain homology to Fe65. All Fe65 proteins
have an identical multimodular structure with three different
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protein–protein interaction domains, a WW domain and two
consecutive PTB domains (9).
During the past years, screenings for Fe65 binding partners
led to the identification of many proteins. APP was the first
binding partner of Fe65 that has been identified, and this inter-
action is highly conserved as all Fe65s examined so far are able
to bind through their C-terminal PTB domain (PTB2) to the
NPTY-containing region of all APP and APP-like proteins.
Phosphorylation of Thr-668 of APP has been shown to impair
Fe65 binding, suggesting a possible ‘‘molecular switch’’ mecha-
nism to regulate the Fe65–APP interaction (10). Recently,
another ligand of Fe65 PTB2 domain, the small G-protein Dex-
ras1, has been shown to bind Fe65, in a noncompetitive way
with APP, and this binding is reduced by the phosphorylation
of Y547 within the Fe65 PTB2 (11). Differently, the N-terminal
PTB domain of Fe65 (PTB1) binds several proteins, such as the
transcription factor CP2/LSF/LBP1 (12), the histone acetyltrans-
ferase Tip60 (13), and the lipoprotein receptors (14). Further-
more, this PTB1 domain of Fe65 binds the N-terminal domain
of Tau protein and their interaction is regulated by Tau phos-
phorylation (15). The WW domain of FE65 binds the proline-
containing motif of Mena, the mammalian homolog of enabled,
which is involved in the control of cell motility through regula-
tion of the actin cytoskeleton (16). Another ligand of the WW
domain is the c-Abl tyrosine kinase, which phosphorylates APP
on Tyr-682 (17, 18) and Fe65 on Tyr-547, within the PTB2 do-
main (19). The member of INHAT complex SET/TAF1-b binds
to a region of Fe65 overlapping the WW domain (20). Fe65
simultaneously recruits SET and Teashirt3, which in turn binds
to histone deacetylases (21).
Fe65 interactions could be regulated by conformational
changes and/or post-translational modifications. In 2004, Cao
and Su¨dhof (22) proposed a model in which Fe65 is inhibited
by an intramolecular interaction of the WW domain with the
PTB domains that can keep Fe65 in a ‘‘closed’’ inactive state.
Data from structural studies showed that this intramolecular
interaction is weak and easy to be opened by the binding of
WW domain or PTB domains to their high-affinity ligands (23).
Therefore, the binding of PTB2 to APP could induce the struc-
tural change that opens Fe65, thus allowing to unmask the
PTB1 and WW domains that become available for their binding
partners.
THE PHENOTYPE OF Fe65 NULL ANIMALS
The study of the alterations observed in KO mice is the ideal
shortcut to get information about the function of a protein.
Unfortunately, the Fe65 null mice have no obvious phenotypes,
perhaps because the two Fe65 paralogs, Fe65L1 and L2, having
similar structure and a great sequence similarity, could be able
to substitute, at least in part, for Fe65. Therefore, the first data
on the effects of Fe65 gene ablation came from Caenorhabditis
elegans, in which only one orthologous gene (feh-1) is present.
The feh-1 null worms either arrest during the early steps of
embryo development or, if this block is escaped, they arrest at
the larval stage L1. In these arrested larvae, the functional
defect consists of impaired feeding ability due to increased rate
of pharyngeal contraction (24, 25), a phenotype similar to that
caused by the suppression of the nematode ortholog of APP. To
get an evident phenotype in mammals, two genes, Fe65 and
Fe65L1, should be ablated. These mice show cortical dysplasia
(26), also in this case similar to that observed in the triple KO
of the APP family members, APP, APLP1, and APLP2 (27).
Although apparently normal, the Fe65 null mice have some
subtle defects. Indeed, they show learning and memory impair-
ment and defective early-phase LTP at the Shaffer collateral-
CA1 synapses (28). Moreover, Fe65 null mice show enhanced
neurogenesis (29), similar to that observed in APP2/2 mice, as
well as a slight increase of GnRH-1 neurons during develop-
ment (30). In another set of experiments, it was demonstrated
that Fe65 null mice are more sensitive to DNA-damaging
agents, as etoposide and ionizing radiations (31).
The molecular bases of these defects are still not definitively
addressed and various possible explanations have been
proposed.
Fe65 AS A REGULATOR OF APP PROTEOLYTIC
PROCESSING
The discovery of Fe65 and of the other partners of APP
cytodomain raised the possibility that these proteins could be
involved in the proteolytic processing of APP and in the genera-
tion of Ab, therefore perhaps relevant for AD pathology. APP
is a type I membrane protein with a large extracellular/intralu-
minal (EC/IL) domain, a single transmembrane tract, and a
short cytosolic domain. APP EC/IL domain can be cleaved by
two enzymes, a-secretase or b-secretase, acting at two different
sites near the EC/IL layer of the membrane. These cleavages
result in the shedding of the APP N-terminal domain in the EC
or IL environment (sAPP). The resulting transmembrane stubs,
called C83 or C99, respectively, are then cleaved by c-secretase
giving rise to the P3 fragment or to the Ab peptides of various
lengths, mostly of 40 or 42 residues (1). The cleavage catalyzed
by the c-secretase also causes the formation of a C-terminal
fragment, released in the cytosol, called APP intracellular
domain (AICD).
The regulation of APP processing is of obvious interest,
because APP fragments, including Ab, could have important
functional and/or pathological roles. It is clearly established that
APP processing depends on the trafficking of the molecule
among various intracellular compartments. In particular, muta-
tion of the internalization signal YENPTY of the cytodomain of
APP blocks endocytic trafficking and decreases Ab production
(32). Considering that this motif is the binding site of Fe65, it
can be hypothesized that the binding of Fe65 to APP influences
the endocytosis and in turn the processing. Experimental evi-
dence did not help to definitively address this point. Indeed,
there are reports indicating that Ab production is increased by
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Fe65 overexpression (33) and reduced by Fe65 knockdown
(34), whereas other studies reported that FE65 increased sAPPa
and decreased Ab production (10). Apparently, the results
obtained in animal models are similarly conflicting: APP
knock-in mice carrying the Y682G mutation, which abolishes
the binding of Fe65, showed decreased levels of Ab and a mas-
sive increase in soluble APPa (35). However, the brain of trans-
genic mice overexpressing Fe65 contains reduced deposits of
Ab (36). Furthermore, mutations of T688 in the APP cytodo-
main, whose phosphorylation prevents Fe65 binding, does not
affect the physiological processing of APP in knock-in animals
(35). Lastly, in the Fe65/Fe65L1 double KO (DKO) mice, no
difference was observed in sAPP between wild type (wt) and
DKO mice, whereas a slight decrease of Ab42 was present only
in DKO male mice (26). The reasons for these apparently con-
flicting results are not clear. The complexity of the protein–pro-
tein interaction network centered at the YENPTY motif of the
cytodomain of APP renders the phenomenon very difficult to
dissect with loss or gain of function experiments. Furthermore,
the proteolytic processing is also under the control of other
likely unrelated events such as cell-type-specific intracellular
trafficking and regulation of secretases.
Fe65, CYTOSKELETON REMODELING, AND
CELL MOVEMENT
Having the characteristics of an adaptor protein, Fe65 was
expected to interact with other proteins, further than APP. Mena
was the first protein identified to interact with the WW domain
of Fe65 (16). Mena belongs to a small family of proteins
involved in the control of cell movement and morphology and
in chemotactic responses (37). It was demonstrated that Fe65
and APP are present in dynamic adhesion complexes present on
the surface of the cells and that their overexpression causes the
acceleration of cell migration (38). Therefore, it can be specu-
lated that an APP/Fe65/Mena complex is involved in the regula-
tion of cell movement. This hypothesis is supported by further
observations indicating that Fe65 and APP are also present in
growth cones and synapses, mostly at the level of actin-rich
lamellipodia (39). The neuropathological phenotype of the
Fe65/Fe65L1 (26) DKO mice and those of the triple KO of
APP/APLP1/APLP2 (27) or Mena/VASP/EVL (36) could be
interpreted as defects of cell movement, thus confirming the
possible role of Fe65 in this function. The Drosophila orthologs
of the mammalian Mena and mDab1 genes are genetic modula-
tors of the phenotype observed in flies null for the Abl tyrosine
kinase. Therefore, the observations that mDab1 and Mena,
directly or indirectly through Fe65, interact with APP reinforce
the possibility that all these proteins are involved in a single
pathway. Furthermore, we found that Fe65, through its WW
domain, binds in vitro and in vivo the active form of Abl. The
latter, recruited by Fe65 close to APP, phosphorylates a tyrosine
residue of its cytodomain and then binds to this phospho-APP
(17).
One important point that requires to be addressed is the role
of the competition among the various players of this machinery,
as Mena and Abl are expected to compete for the binding to the
WW of Fe65, which in turn should compete with mDab1 and
Abl for the interaction with APP. Figure 1 shows only some of
the possible complexes that can be formed by the above-men-
tioned proteins. Among the various hypothetical models that
can be assembled, one of particular interest is based on the
Figure 1. Possible competition among members of the APP-cen-
tered machinery. Mena belongs to the Ena/VASP family of
regulators of actin dynamics and cell movement. Genetic experi-
ments in Drosophila and many results obtained in mammalian
cells support the possibility that the tyrosine kinase Abl and the
Dab1 protein, the mammalian ortholog of Drosophila disabled,
antagonize the effects of Mena on actin cytoskeleton and cell
movements. The figure shows three possible scenarios of the
competition among these molecules for the binding to the APP
cytodomain. In panel a, Dab1 is associated with APP, thus Fe65
is in the ‘‘close’’ conformation and unable to interact with Mena.
In panel b, Fe65 has displaced Dab1, acquired the active confor-
mation, and thus can bind to Mena. In panel c, activated Abl
competes with Mena for the binding to the WW domain of Fe65,
thus Mena is displaced. Based on the phenotypes observed by
manipulating the amounts of Abl, Dab, and Ena, it can be specu-
lated that the interaction with Fe65 inhibits Mena activity and, in
turn, Dab and active Abl, which prevent Mena–Fe65 interaction,
favor the activity of Mena. [Color figure can be viewed in the
online issue, which is available at wileyonlinelibrary.com.]
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competition between Dab1 and Fe65 for the binding to APP
cytodomain. When Dab1 occupies the APP site, Fe65 is in the
‘‘closed’’ conformation (see above) that is unable to interact
with Mena, being the WW domain masked. In these conditions,
Mena is available to regulate cytoskeleton. Conversely, when
Fe65 displaces Dab1 and binds to APP cytodomain, its WW
domain is available for the binding to Mena, which in turn will
be sequestered in an inactive form or in an irrelevant compart-
ment. This scenario could be further modified by the activation
of Abl, which competes with Mena for the binding to the WW
of Fe65, thus liberating Mena in its active form and/or toward
its relevant compartment. Obviously, the model could be further
modulated by the involvement of other ligands of APP and
Fe65.
NUCLEAR Fe65 AND THE REGULATION OF GENE
TRANSCRIPTION
The possible nuclear functions of Fe65 are no less intriguing
than those described in the previous paragraphs. The starting
point in this case was the observation that Fe65 is also present
in the nucleus and that its interaction with APP regulates its
nuclear translocation (40). Other results indicated that further
transcription factors or cofactors could be recruited at gene pro-
moters associated with Fe65. This is the case, among the others,
of: (i) late SV40 factor (LSF), whose interaction with the PTB1
domain of Fe65 affects the regulation of the thymidylate syn-
thase gene (41); (ii) estrogen receptor a, through which estrogen
appears to modulate the activity of Fe65-containing complex
(42); (iii) SET, a component of the inhibitor of histone acetyl-
transferases (20); and (iv) Teashirt, which, together with SET,
regulates the caspase 4 gene (21).
Another important study reported that nuclear Fe65 interacts
with the histone acetyltransferases Tip60 and that the Fe65–
Tip60 complex is able to activate the transcription from syn-
thetic gene promoters (13). A very interesting point that
emerged from this work is that the cytosolic fragment of APP,
AICD, may take part in this machinery by forming a heterotri-
meric complex with Fe65 and Tip60. The obvious relevance of
this finding is that it suggested the possible similarity between
the APP-centered complex and Notch. Indeed, Notch is a mem-
brane-tethered transcription factor that, as a consequence of a
proteolytic processing catalyzed by c-secretase, liberates the
Notch cytosolic domain (NICD). The latter goes into the nu-
cleus, where in association with other proteins regulates the
transcription of key developmental and differentiation genes
(43). Therefore, AICD could function like NICD, together with
Fe65, Tip60, and other proteins. Many research groups tried to
address the AICD-dependent regulation of transcription; how-
ever, the results obtained so far still leave numerous doubts.
Several genes have been suggested to be direct targets of
AICD–Fe65, like APP itself, BACE, Tip60, KAI1, LRP, neprily-
sin, and Stathmin1 (44–47); however, a systematic analysis of
the Fe65-binding sites in the mammalian genome is still not
available. However, conflicting results are instead available on
the role of the APP processing in gene regulation. Indeed,
genetic and/or pharmacological suppression of c-secretase gave
very different results or was not effective on the regulation of
the above-mentioned genes (48, 49). Therefore, the demonstra-
tion that AICD, through its interaction with Fe65, regulates
gene expression is still lacking.
Fe65 IN THE CELLULAR RESPONSE TO DNA DAMAGE
The presence of Fe65 in the nucleus, associated with Tip60,
does not imply its involvement exclusively in gene regulation.
Indeed, Tip60 has a key role in the response to DNA damage,
with the dual role of histone and ataxia telangiectasia mutated
(ATM) acetyltransferase (50). The study of the phenotype of
Fe65 null mice led to the observation that these mice are more
sensitive to DNA-damaging agents (31). Low doses of etopo-
side or H2O2, which have only marginal effects on wt mouse
embryo fibroblasts (MEFs), induced high levels of DNA dam-
age and accumulation of c-H2AX in Fe65 KO mouse embryo
fibroblasts (MEFs). Irradiated mice showed a similar accumula-
tion of c-H2AX. Genotoxic stress induced by sorbitol causes
the nuclear translocation of Fe65 in an APP-dependent manner
(51). In this experimental system, Fe65 nuclear translocation
precedes c-H2AX accumulation, and the latter is decreased in
the absence of Fe65. Therefore, it seems that nuclear Fe65 plays
a key role in the response of the cell to DNA damage. Further-
more, the results available so far suggest that nuclear Fe65
should be in a specific conformation, which could depend on its
interaction with APP (induction of open conformation; see ref.
22). Another possibility is that the activation of Fe65 also
depends on post-translational modification on DNA damage.
This possibility is supported by the observation that the electro-
phoretic migration of nuclear Fe65 is modified, likely due to
phosphorylation, within few minutes from DNA damage (31).
The molecular mechanisms underlying the function of Fe65 in
the nucleus of cells exposed to DNA-damaging agents are still not
completely understood. A first set of experiments demonstrated
that the Fe65 knockdown hampers the recruitment of Tip60 at
DNA strand breaks and in turn the acetylation of histone H4 (52).
This event could explain the defects in the DNA damage response
and in the DNA repair observed as a consequence of Fe65 sup-
pression. One possibility is that active Fe65 functions as a scaffold
protein that interacts with chromatin, thus favoring the recruitment
of soluble Tip60. In addition, nuclear Fe65 stabilizes p53 (53),
and this could be a further mechanism through which Fe65 con-
tributes to the response of the cells to DNA damage.
In this case, the crosstalk between Fe65 and APP/AICD also
remains to be addressed. The first issue is concerned with the
possible regulation of Fe65 nuclear translocation on DNA dam-
age. One interesting possibility is that Fe65, bound to APP
cytodomain and thus in its ‘‘open’’ active conformation, is
released from APP as a consequence of APP phosphorylation at
Thr668, possibly catalyzed by c-Jun N-terminal kinase JNK
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(54). Nuclear Fe65 is then rapidly modified, likely phosphoryl-
ated, and it is necessary for Tip60 recruitment at the DNA
breaks (see Fig. 2). Of course, Fe65 suppression leads to
reduced phosphorylation of H2AX and decreased efficiency of
DNA repair (52). The crucial involvement of APP in this ma-
chinery is supported by the observation that APP/APLP2 knock-
down has the same effects observed with Fe65 suppression, that
is, reduced recruitment of Tip60 at DNA breaks and reduced
histone H4 acetylation (52). Considering that AICD seems not
to be necessary in this machinery, the most likely explanation
for the role of APP in the mechanism is that the interaction of
Fe65 with APP is necessary to allow Fe65 to acquire the proper
conformation.
CONCLUSIONS
Despite the large literature on the function of Fe65 and on the
consequences of its interaction with APP, many questions are
still waiting for a definitive answer. Similarly, the possibility
that Fe65 dysfunction could have any role in AD is far to be
addressed. The information accumulated up to now is surprising,
because Fe65 seems to be involved in several different functions.
The number of proteins that appear to have more than one func-
tion is growing; however, in many cases, this multiplicity of
functions is probably due to the incomplete understanding of the
protein. This is obviously the case of Fe65. Robust data indicate
that Fe65 is an adaptor protein with a wide choice of possible
interactors. It shuttles between two intracellular compartments: in
the cytosol, it could be involved with APP, Mena, mDab1, and
Abl in the regulation of cell movement; and in the nucleus, in
connection with transcription factors and/or histone-modifying
enzymes, it could play a role in the response to DNA damage
and/or in transcription regulation. In both cases, the proteolytic
processing of APP and/or its post-translational modifications
could be affected by Fe65 and regulate Fe65 intracellular traffick-
ing. A speculation that deserves to be explored in detail is that
Fe65 and its partners are part of a molecular machinery working
during development and differentiation and are involved in a
concerted cellular response to stress conditions.
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